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ABSTRACT 
The overall goal of my thesis was to determine the feasibility of dried blood spots (DBS) 
technology for measurement of topiramate (TPM) concentration and characterization of 
the relationship between whole blood and plasma TPM concentrations.  Topiramate is 
widely used in the treatment of epilepsy and migraines and has shown to be effective in 
controlling seizures in children and adults.  Topiramate has the potential to be a good 
therapy for neonatal seizures and Dravet syndrome.  One major hurdle in developing 
drugs for treatment of childhood seizure disorders is the severe restriction on blood 
sampling in critically ill children, in whom blood is collected for a multitude of lab tests.  
This circumstance reduces the blood volume available for pharmacokinetics (PK) studies.  
Consequently, the necessary research on PK and dose finding is often significantly 
limited. 
 
The relationship between whole blood and plasma TPM concentrations were explored in 
canines with naturally-occurring epilepsy and adult and children on maintenance TPM 
therapy.  In addition, the PK was described in both of these populations.  In the canine 
study, four dogs were administered both intravenous (IV) and oral topiramate with the 
goal of comparing the PK of IV TPM in plasma and whole blood and describing the 
relationship between whole blood and plasma TPM concentrations.  Similar to humans, 
the study showed a nonlinear relationship between plasma and whole blood TPM 
concentration in which whole blood TPM concentrations were 1.3-3.7 times greater than 
plasma concentrations.  In addition, there was a difference in PK parameter estimates 
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with those derived from whole blood generally showing reduced clearances resulting in 
longer elimination half-lives.  
 
In the adult and children study, thirty adult and eight children participants currently 
taking TPM therapy were recruited.  These studies provide previously unreported 
information about TPM.  Whole blood concentrations were found to be different than 
plasma concentrations with the whole blood TPM concentrations 0.9-4.4 times greater 
than plasma concentrations.  These are the first studies comparing plasma and DBS TPM 
concentration obtained from patient samples using a formula that includes both 
hematocrit and the analyte-specific red blood cell-to-plasma ratio.  The calculated TPM 
plasma concentration based on whole blood and DBS concentrations are in good 
agreement with analyzed plasma concentrations.  Additionally, the PK of TPM was found 
to be similar to previous reported literature values.     
 
This thesis describes the development of bioanalytical assays to the implementation of 
these assays in clinical practice and clinical pharmacologic aspects of topiramate PK.  
Results from the studies described in this thesis provide a tool to estimate plasma 
concentrations from whole blood or DBS TPM concentrations.  This will allow 
therapeutic drug monitoring using DBS and permit PK studies in populations where 
blood volume is limited.   
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CHAPTER 1: INTRODUCTION TO CHILDHOOD EPILEPSIES  
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1.1. EPILEPSY  
The International League Against Epilepsy (ILAE) defines epilepsy as a condition 
characterized by recurrent (two or more) unprovoked seizures separated by more than 24 
hours and an alteration in the brain that increases the likelihood of future seizures.
1
  A 
seizure is the clinical manifestation of an abnormal and excessive activity of a set of 
cortical neurons. 
 
The focus of the research presented in this thesis involves understanding the relationship 
between whole blood and plasma TPM concentrations.  The following two chapters will 
summarize pediatric epilepsy syndromes with an emphasis on disorders that use or have 
potential use of TPM and development pharmacokinetics and pharmacotherapy in 
children as it relates to these disorders.    
 
Table 1: Operational Clinical Definition of Epilepsy
1
  
Epilepsy is a disease of the brain defined by any of the following conditions 
1. At least two unprovoked seizures occurring > 24 h apart 
2. One unprovoked seizure and a probability of further seizures similar to the 
general recurrence risk (at least 60%) after two unprovoked seizures, occurring 
over the next 10 years 
3. Diagnosis of an epilepsy syndrome 
Epilepsy is considered to be resolved for individuals who had an age-dependent epilepsy 
syndrome but are now past the applicable age or those who have remained seizure-free 
for the last 10 years, with no seizure medicine for the last 5 years 
 
1.2. EPIDEMIOLOGY 
When considered a group, epilepsy disorders are among the most frequently occurring 
neurologic conditions in children.
2
  In the United States approximately 5% of children 
and adolescents experience a seizure of some type by the age of 20.
2
  Incidence rates for 
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epilepsy have been estimated over the past several years and have been found to range 
from 35 to 124 per 100,000 in different countries.
2
  Numerous studies have discussed the 
prevalence of epilepsy worldwide.  The definitions of prevalence vary, however, if 
prevalence is defined as seizures or medication in the past 5 years, estimates remain 
between 3 and 7 per 1,000 in developed countries and in the range of 9 to 22 per 1,000 in 
developing countries.
2
  
 
1.3. CLASSIFICATION OF EPILEPTIC SEIZURES 
A classification of epileptic seizures provides guidance in determining the diagnostic 
evaluation, treatment, and prognosis.  In 2010 the ILAE proposed a revision of the 
terminology and concepts for organization of seizures.
3
  The new terminology will be 
used.  
 
1.3.1. Focal Seizures 
Focal seizures arise in specific loci in the cortex within networks limited to one 
hemisphere.  They can be classified further into those without impairment of 
consciousness or awareness and those with impairment of consciousness or awareness.  
In patients not demonstrating impairment of consciousness or awareness, focal seizures is 
further subdivided into seizures with: (i) observable motor or autonomic components and 
(ii) subjective sensory or psychic phenomenon.
4
  The signs and symptoms of focal 
seizures depend on the location of the seizure.  Seizures involving the motor cortex most 
commonly consist of rhythmic clonic activity of the face, arm, or leg.  Seizures with 
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somatosensory, autonomic, and psychic symptoms may involve hallucinations, illusions, 
and déjà vu. 
 
Focal seizures with impairment of consciousness are one of the most common seizure 
types encountered in both children and adults.
2
  Focal seizures without impairment of 
consciousness may evolve into seizures with impaired consciousness.  The beginning of 
the focal seizure may serve as a warning to the patient (i.e. aura) that a more severe 
seizure is pending.  The impairment of awareness may be subtle.  The patient may either 
not respond to commands or respond in an abnormally slow manner.  Behavior is usually 
more complex during the seizure.  Automatisms, of which the patient is unaware and 
subsequently cannot recall, are common during the period of impaired consciousness.  
Types of automatism behaviors are variable and may consist of activities such as facial 
grimacing, gestures, chewing, lip smacking, snapping fingers, and repeating phases.   
 
Although variable, focal seizures usually last from 30 seconds to several minutes.
4
  Most 
patients have some degree of postictal impairment, such as tiredness or confusion 
following a focal seizure. 
  
1.3.2. Generalized Seizures     
Generalized seizures involve large areas of the brain and are usually bilateral in their 
initial manifestations and associated with early impairment of consciousness.  These can 
range from absence seizures, characterized only by impaired consciousness, to 
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generalized tonic-clonic seizures (GTC), in which widespread convulsive activity takes 
place.  
 
Generalized Tonic-Clonic Seizures 
GTC seizures are characterized by loss of consciousness that occurs simultaneously with 
the onset of a generalized stiffening of flexor or extensor muscle (termed tonic phase).  
Following the tonic phase, generalized jerking of the muscles (clonic activity) occurs.     
 
Absence Seizures 
Absence seizures are generalized seizures, indicating bihemispheric initial involvement 
clinically and electroencephalographically.  Absence seizures have an abrupt onset and 
offset.  There is typically a sudden cessation of activities with a blank, distant look to the 
face.  As the seizure continues, there are often automatism and mild clonic motor activity 
such as jerks of the arms and eye blinking.  The two major divisions of absence seizures 
are typical and atypical.    
 
Simple atypical absence consists of the sudden onset of impaired consciousness, usually 
associated with a “blank” or “distant” facial appearance without other motor or 
behavioral phenomena.  The complex typical absence is accompanied by other motor, 
behavioral, or autonomic phenomena.  Atypical absence seizures are characterized as 
having more pronounced change in tone and longer duration than typical seizures.    
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Clonic Seizures 
Clonic seizures have rhythmic or semirhythmic contractions of a group of muscles.  
These jerks can involve any muscle group although the arms, neck, and facial muscles are 
most commonly involved.  Clonic seizures are more common in children than adults.
4
   
 
Myoclonic Seizures 
Myoclonic seizures are characterized by sudden, brief (<350 milliseconds), shock-like 
contraction that may be generalized or confined to the face and trunk or to one or more 
extremities.  Myoclonic seizures result in short bursts of synchronized electromyographic 
activity which often involves simultaneous activation of agonist and antagonist muscles.  
The muscle contractions are quicker than the contractions with clonic seizures.  These 
seizures may be dramatic, causing the patient to fall to the ground or may be quite subtle, 
resembling tremors.  Because of the brevity of the seizures, it is not possible to determine 
if consciousness is impaired.      
 
Tonic Seizures 
Tonic seizures are brief seizures (usually less than 60 seconds) consisting of the sudden 
onset of increased tone in extensor muscles.  If standing, the patient typically falls to the 
ground.  The seizures are invariably longer than myoclonic seizures.  There is impairment 
of consciousness during the seizure, although in short seizures this may be difficult to 
assess.  
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Atonic Seizures 
Atonic seizures or drop attacks are characterized by a sudden loss of muscle tone.  They 
begin without warning and cause the patient, if standing, to fall quickly to the floor.  
Since there may be a total loss of tone, the child has no means to protect himself and 
injuries often occur.  Consciousness is impaired during the fall, although the patient may 
regain alertness immediately upon hitting the floor.  Atonic attacks are frequently 
associated with myoclonic jerks either before, during, or after the atonic seizure.
4
 
 
1.4. EPILEPSY SYNDROMES 
There are a number of age-related syndromes which have been discussed in detail.
2,4
  For 
this introduction, a summary of the epidemiology, etiology, and clinical course for 
selective childhood epilepsies will be described.  A detailed discussion of all syndromes 
is beyond the scope of this introduction and can be found in “Pediatric Epilepsy” and 
“Pediatric epilepsy: diagnosis and therapy”.2,4 
 
1.4.1. Newborns 
Neonatal Seizures 
The risk of seizures in newborns is significant and diagnosis for this disease is often hard 
because seizures are difficult to detect in newborns.   
 
Epidemiology and Etiology 
Neonatal seizures are defined as seizures occurring during the first 30 days of life.  The 
incidence of seizures in children is significantly higher than in adults with the greatest 
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risk being in the neonatal period.
  
Neonatal seizures are estimated to occur in 0.01% of 
live births (1-5/1000 live births).
5,6
  This estimate has varied from 0.5% in term babies to 
22.2% in preterm babies.
5,7-9
   
 
Hypoxic ischemic encephalopathy (HIE) is the most common cause of neonatal 
seizures.
10,11
  HIE is characterized by oxygen deprivation to the brain.  This is commonly 
due to brain injury from asphyxia.  HIE is presumed to be the cause in 50% to 60% of 
neonatal seizure cases.
10,11
  A range of factors can also increase the risk of neonatal 
seizures which include inborn errors of metabolism, intracranial hemorrhaging, 
infections, and metabolic irregularities.  In a study of 200 neonates, etiology was 
identified in 99% of cases.  Birth asphyxia was the most common (35%) followed by 
CNS infections (34%), metabolic abnormalities (12.5%), and intracranial bleeding 
(9.5%).
12
  In addition gestational age is suggested to play a role in the risk for developing 
neonatal seizures.  The risk of seizures increases in preterm infants and infant with low 
birth weight.
10,13
   
 
Pathophysiology  
The early postnatal period represents a critical developmental window in which 
synaptogenesis is ongoing and neuronal plasticity is increased compared to adults.  
Excitatory synaptic transmission mediated by glutamate receptors is required for these 
processes and is enhanced in the immature brain.
14
  Glutamate, a major excitatory 
neurotransmitter, has been shown to be important in the development of plasticity.  The 
synapse with receptor localization is illustrated in Figure 1.  
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Figure 1: Dynamics of Synaptic Transmission at Cortical Synapses in the Neonatal 
Period
15
  
 
Glutamate receptors (GluRs) are transiently overexpressed during development (Figure 
2).
16
  There are two types of GluRs, ionotropic and metabotropic.  Ionotropic GluRs are 
ligand-gated ion channels that permit the flux of sodium, potassium, and sometimes 
calcium ions.
14
  The main subtypes of these receptors include the N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and kainate 
receptors.   
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Figure 2: Schematic depiction of maturational changes in glutamate and GABA 
receptor function in the developing brain
17
 
 
NMDA receptors are heteromeric, including an obligate NR1 subunit, and their makeup 
is developmentally regulated.
16
  In the neonatal brain, the predominant NR2 subunit is the 
NR2B and functionally results in a longer current decay time compared to the adult 
NR2A subunit.
16
  Other subunits, NR2C, NR2D, and NR3A, have decreased magnesium 
sensitivity causing increased receptor excitability.
18
  Even though this receptor presents 
an age-specific therapeutic target, a barrier in drug development is that it is essential for 
learning, memory, and brain development.
16
   
 
The AMPA glutamate receptors are suggested to be involved in fast excitatory synaptic 
transmission.  These receptors are hetreomeric and composed of four subunits (GluR1, 
GluR2, GluR3, or GluR4).  In the immature brain, AMPA receptors lack the GluR2 
11 
 
subunit compared to the adult brain, which leads to increased calcium influx.
19
  This 
AMPA receptor composition enhances receptor excitability during the neonatal period.   
 
The developmental regulation of metabotropic glutamate receptors is not well known.  
The metabotropic glutamate receptor subunits are mGluR1 through mGluR8 and are 
divided into three groups based on receptor structure and physiological activity (Group I: 
mGluR1 and mGluR5, Group II: mGluR2 and mGluR3, Group III: mGluR4, mGluR6, 
mGluR7, and mGluR8).  Recently a study in rats showed that mGluR1 expression might 
peak in the first postnatal week, whereas mGluR2, mGluR3, and mGluR5 levels mature 
by the second postnatal week.
20
  Structural features of metabotropic GluRs may offer new 
targets for anticonvulsants.  Specifically, group II and group III metabotropic GluR 
agonists have anticonvulsant properties.
20
  
    
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain.  
The expression and function of GABA receptors are developmentally regulated and may 
play an influence in neonatal seizures.  Binding and expression of the GABA receptor are 
both lower in the immature brain compared to the adult human and animal brain.
14
  
GABA receptor activity is regulated by subunit expression and composition.  In the 
neonatal brain, the α4 and α2 subunits are overexpressed and the α1 subunit is under 
expressed compared to adult brain.
21
   Overexpression of the α4 subunit decreases GABA 
receptor sensitivity to benzodiazepines.
21
  The two classes of GABA receptors, GABAA 
and GABAB, have distinct functions.  In the first postnatal week, activation of GABAA 
receptors causes membrane depolarization rather than the hyperpolarization typical of 
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mature GABA-ergic synapses.
14
  This depolarization is due to a reversed chloride 
gradient in the developing brain attributable to decreased expression of the chloride 
exporter potassium-chloride co-transporter (KCC2) and the overexpression of the 
calcium importer, NKCC1.
22
  Full maturation of these receptors is reached within 2 years 
of age.   
 
Clinical Course 
Neonatal seizures can significantly affect mortality and morbidity.  Current therapies 
have improved the outcomes for neonatal seizures; however, long-term neurological 
sequelae have not changed.  The Collaborative Perinatal Project, which studied the 
outcomes of neonatal seizures in 277 infants from 1959-1966, reported a 35% mortality 
rate with 30% of the survivors having long-term adverse neurological outcomes at 7 
years of age including cerebral palsy (13%), intelligence quotient less than 70 (19%), and 
epilepsy (20%).
23
  In a recent study, mortality was found to be much lower at 7%, but 
poor long-term neurological outcomes remained the same as decades earlier.
24
   
 
Long-term neurological outcomes can include cognitive and behavioral disabilities and 
epilepsy.  The severity of adverse outcomes can be associated with severe 
encephalopathy, cerebral dysgenesis, complicated intraventricular hemorrhage, infections 
in the preterm infants, abnormal neonatal EEGs, and the need for multiple drugs to treat 
the neonatal seizures.
25
  Cognitive changes can consist of mental retardation and learning 
disabilities.  Incidence of cognitive effects has been reported to be 20 to 67%.
25,26
  These 
changes are thought to be due to loss of hippocampal synchronized network discharge or 
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loss of hippocampal pyramidal cells.
27
   Neonatal seizures may have subtle 
neurodevelopmental vulnerability on behavioral and learning abilities.  This may become 
evident in specific learning difficulties or poor social adjustment.  In a study of survivors 
of neonatal seizures, mortality outcome of the children was low.  However, the entire 
sample displayed abnormal neuropsychological development in terms of intelligence test 
profile and subtest scatter, or development of spelling, or development of memory.
28
  
 
Epilepsy is a common long-term neurological outcome associated with neonatal seizures.  
For many children, permanent fixed brain injuries, such as resolving stroke, ischemia, or 
traumatic lesions, serve as the nidus for future epilepsy.
11
  Repeated neonatal seizures 
may have “instructed” the brain how to have future seizures, resulting in a persistent 
lowering of the seizure threshold and the development of chronic epilepsy.  
Approximately 17 to 30% of survivors of neonatal seizures experienced one or more 
seizures up to 7 years of age, nearly two-thirds of the seizures occurred within the first 6 
months of life.
11,26,28,29
  Little research has been done to examine development beyond 
seven years of age.   
   
1.4.2. Infancy 
Infantile Spasms 
Infantile spasms are a unique disorder that occurs almost exclusively in infancy (the first 
year of life).  Infantile spasms usually are associated with developmental retardation or 
deterioration and a characteristic EEG pattern that together form a syndrome.
30
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Epidemiology and Etiology 
The onset of infantile spasms most commonly occurs between 3 and 8 months of age 
with a peak at 6 months.
2,30
  Over 90% of cases begin before 12 months of life.
4
  It is 
slightly more common in males, accounting for about 60% of cases.  The incidence of 
infantile spasm is 1 per 2,000-4,000 live births and the prevalence rate is 0.15-0.2 per 
1,000 children of age 10 years or younger.
4
  The information for familial occurrence is 
limited.  The percentage of patients who have a family member with infantile spasms has 
ranged from none to 7%.
2,4
 
 
Infantile spasms have multiple causes, but the mechanisms by which they occur are not 
completely understood.  Infantile spasms are  classified into three main categories –
genetic, structural/metabolic, and unknown according to the ILAE .
4,31
  Cryptogenic 
infantile spasms is the terminology used when there are no apparent causes identified 
although a cause is suspected, usually because the child is developmentally delayed or 
has some other neurological impairment before the onset of the spasms.  Cryptogenic 
cases account for 9%-15% of infantile spasms cases.
4
  Idiopathic is used to describe 
children with no identifiable cause and who have a normal neurological examination and 
normal development prior to the onset of infantile spasms.  The number of genes 
associated with infantile spasms are rapidly increasing (ARX, CDKL5, FOXG, GRIN1, 
GRIN 2A, MAGI, MEF2C, SLC25A22, SPTANI, STXBP1, and 15q11q13).
31
  
Symptomatic cases are those where there is structural brain abnormality or metabolic 
cause. 
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There are various underlying disorders for symptomatic cases that can be classified into 
prenatal, perinatal, and postnatal groups.  Accounting for over 40% of total cases, 
prenatal etiologies include CNS malformations, chromosomal abnormalities, congenital 
central nervous system infections, and rarely, in-born error of metabolism.  Perinatal 
precipitants include HIE and hypoglycemia.
30
  Postnatal factors include intracranial 
infections, hypoxic-ischemic insults, and brain tumors.  Tuberous sclerosis is a major 
cause of infantile spasms, with up to 50% of all patients with tuberous sclerosis 
presenting with infantile spasms which peak between 4 and 6 months of age.
32
  
 
Clinical Course 
Medical treatment for infantile spasms continues to be a challenge and there is no 
conclusive evidence that treatment alters the developmental or mental outcome in these 
patients.  The prognosis of infantile spasms in terms of neurodevelopmental progress and 
the development of other types of seizures remain poor despite treatment.  The clinical 
spasms and EEG hypsarrhythimia (abnormal interictal pattern consisting of high 
amplitude and irregular waves and spikes) pattern tends to disappear spontaneously by 3-
4 years of age.  However, up to 60% of these children will go on to develop other types 
of seizures.
4
 
 
Reviews of studies of long-term outcomes for patients with infantile spasms suggest only 
16% of the patients had normal development.
33
  Mental retardation is common in 
patients.  Symptomatic patients experience a higher rate of seizure occurrence (54%) 
compared to cryptogenic patients (23%).
4,33
  In addition, the percentage of cryptogenic 
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patients with normal development (51%) was significantly higher than that of 
symptomatic patients (6%) particularly if treatment has been started within 1 month.
31,33
  
It is suggested that better initial control of spasms by hormonal treatment in cryptogenic 
or idiopathic cases of infantile spasms may lead to improved developmental outcome.  
There is growing evidence that longer duration of spasms is associated with poorer 
neurodevelopmental outcomes such as developmental delay and autistic behavior.
34
  
Spontaneous remission of spasms and disappearance of hypsarrhythimia in untreated 
patients have been reported in 25% of children by 1 year of age, but overall, the 
developmental outcome in infantile spasms is poor.
35
 
 
Febrile Seizures 
The ILAE defines a febrile seizure as “a seizure in association with a febrile illness in the 
absence of a CNS infection or acute electrolyte imbalance in children older than 1 month 
of age without prior afebrile seizures”.  The temperature associated with the febrile 
illness must be greater than 38.4°C.
2
  Febrile seizures can be classified as either simple or 
complex.  A simple febrile seizure is isolated, brief, and generalized.  Conversely, a 
complex febrile seizure is focal, multiple, or prolonged, lasting more than 10 or 15 
minutes.   
 
Epidemiology and Etiology 
Febrile seizures are the most common form of childhood seizures, affecting between 2% 
and 4% of children in the United States and Western Europe, 9% to 10% of children in 
Japan
36
, and up to 14% of children in Guam.
37
  The peak incidence of febrile seizures is 
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at approximately 18 months of age with most commonly occurring between 6 months and 
5 years of age.
38
 
 
The factors associated with increased risk of febrile seizures include: (1) a first or second 
degree relative with a history of febrile seizures, (2) a neonatal nursery stay of >30 days, 
(3) developmental delay, or (4) attendance at day care.  There was a 28% chance of 
experiencing at least one febrile seizure for children with two of these factors.
39
  
Approximately one-third of children with a first febrile seizure will experience a 
recurrence; 10% will have three or more febrile seizures.
38
  The most consistent risk 
factors for recurrent febrile seizures are family history, onset of first febrile seizure at <18 
months of age, peak temperature, and the duration of the fever prior to the seizures.
38
  
  
Clinical Course 
The morbidity and mortality associated with febrile seizures are extremely low.  Multiple 
studies have demonstrated no evidence of permanent motor deficits following febrile 
seizures.
40-44
  These studies have also shown that cognitive abilities and school 
performance of children with febrile seizures were similar to those of controls.  Even 
prolonged febrile seizures do not appear to be associated with adverse cognitive 
outcomes.
43,45
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Myoclonic Epilepsies in Infancy and Early Childhood 
There are three types of myoclonic epilepsies in infancy: benign, severe, and myoclonic-
astatic.  The features of the main types of myoclonic epilepsies occurring in younger 
children are shown in Table 2.  This review will focus on Dravet syndrome.   
 
Table 2: Distinctive Features of the Main Types of Myoclonic Epilepsies
2
 
Syndrome Age at 
Onset 
Seizure Type Associated 
Conditions/Etiology 
Prognosis/Outcome 
Benign 
myoclonic 
epilepsy in 
infancy 
4 m-3 y Bilateral jerks; 
spontaneous or 
reflex 
Idiopathic  Excellent in most; 
self-limited 
condition 
Severe 
myoclonic 
epilepsy 
(Dravet 
syndrome) 
3 m-2 y Febrile, 
convulsive, 
unilateral, sleep-
related, falsely 
generalized; 
myoclonic, 
atypical absence 
Progressive mental 
decline 
Poor to very severe; 
mental handicap; 
high risk of SUDEP 
Myoclonic-
astatic 
epilepsy 
(Doose 
syndrome) 
1-4 y Myoclonic; 
astatic; 
myoclonic-astatic; 
absence status 
Idiopathic; 
progressive mental 
deterioration in 
some; ion channel 
disorder 
Excellent to poor; 
self-limited in some 
with offset in 
childhood 
 
Epidemiology and Etiology 
The frequency in the general population is not well known, but has been estimated at 1 
per 40,000 births.
46
  Dravet syndrome represents 3% to 5% of epilepsies with onset in the 
first year of life.
2,47
  Males are more often affected, with a sex ratio of 2.
46,47
 
 
A family history of febrile seizures occurs in up to 71% of Dravet syndrome cases.
48
  In 
addition, mutations in the sodium-channel gene SCN1A have been found in all seven 
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probands.  Subsequent studies have confirmed the presence of this mutation in most, but 
not all patients, with a lesser prevalence in border-line or atypical cases.
49
  
Approximately 70% of patients are mutationally positive.
50
 
 
Clinical Course 
The prognosis for patients with Dravet syndrome is poor.  Seizures tend to persist, all 
patients have cognitive dysfunction, and mortality is high, especially when patients reach 
adolescence and adulthood.
46
  The mortality rate is approximately 15.9-18%.
49
  After the 
regression between ages 1-5 years, mental impairment remains more or less stable.  
Slowness, perseverations, and language impairment are prominent; motor difficulties and 
orthopedic problems are also common.
4
     
 
1.4.3. Childhood 
Lennox-Gaustat Syndrome 
Lennox-Gaustat syndrome (LGS) is a pediatric epilepsy syndrome characterized by 
multiple seizure types; mental retardation or regression; and abnormal findings on 
electroencephalography. 
    
Epidemiology and Etiology 
LGS accounts for 1%-4% of all cases of childhood epilepsy, but 10% of cases start in the 
first 5 years of life.
2,4
 The annual incidence of LGS in childhood is 2 per 100,000 children 
while its prevalence ranges from 0.1 to 0.28 per 1,000 in Europe and the United States.  
The mean age at epilepsy onset is 26 to 28 months (range 1 day-14 years).
51,52
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LGS can be classified according to its suspected etiology as either idiopathic or 
symptomatic.  Patients may be considered to have idiopathic LGS if there is normal 
psychomotor development before the onset of symptoms, if there are no underlying 
disorders or definite presumptive cause, and if there are no neurologic or neuroradiologic 
abnormalities.  In contrast, patients have symptomatic LGS if there is an identifiable 
cause for the syndrome.  Pathologies responsible for LGS include 
encephalitis/meningitis, tuberous sclerosis, brain malformations, birth injury, hypoxic-
ischemic injury, frontal lobe lesions, and trauma.  Infantile spasms precede the 
development of LGS in 9% to 41% of cases.
2,4
  Population-based studies have found that 
22% to 30% of patients have idiopathic LGS, and 70% to 78% have symptomatic 
LGS.
51,53,54
 
 
Clinical Course 
The long-term prognosis for patients with LGS is poor.  Several studies have 
prospectively followed cohorts of children with LGS and demonstrated persistence of 
typical characteristics such as frequent seizures and different seizure types over time in 
many of these children.  Mortality is reported to range from 3% (mean follow-up of 8.5 
years) to 7% (mean follow-up of 9.7 years).
54
   
  
Cognitive dysfunction, psychiatric symptoms, and multiple seizure types are common in 
patients with LGS.  Factors associated with cognitive dysfunction are symptomatic LGS, 
a previous history of infantile spasms, onset of symptoms before 12 to 24 months of age, 
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and higher seizure frequency.  A significant correlation exists between age of onset of 
seizures and mental deterioration, with a favorable cognitive outcome more likely to 
occur in patients with a later age of LGS onset.
55
 
 
Psychiatric symptoms in young children consist of mood instability and personality 
disturbances, while slowing or arrest of psychomotor development and educational 
progress characterize the neuropsychological symptoms.  Character problems 
predominate in older children, and acute psychotic episodes or chronic forms of 
psychosis with aggressiveness, irritability, or social isolation may occur.
54
   
 
Several types of seizures occur in LGS including tonic, atonic, myoclonic, and atypical 
absences, often associated with other less common types.    
 
Absence Epilepsies 
Childhood absence epilepsy (CAE) is characterized by a brief, sudden lapse of 
consciousness that occurs in school age children.  Based on earlier studies, CAE has been 
considered a benign disorder with relatively easily attained seizure control and minimal 
involvement of cognition and behavior.
2
 
 
Epidemiology and Etiology 
Absence seizures comprise 2% to 11% of seizure types in all ages.  Childhood absence 
epilepsy accounts for 8% to 15% of all childhood epilepsies with an incidence of 4.7-8.0 
per 100,000 children between the ages of 1 and 15 years.
56,57
  The average age at 
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presentation is 6 years (range 2-10 years) with previous febrile seizures reported in 
11%.
58
 
 
The etiology of absence epilepsy is suggested to be complex involving both acquired and 
inherited factors.  Recent investigations found calcium channels and GABA receptors to 
be associated with absence epilepsy.
2,4
    
  
Clinical Course 
Children with absence epilepsy have a good prognosis.  Most (65%) become and remain 
seizure free with the average age of cessation of absence seizures being 10.5 years.
57
  A 
small population (7%-9%) have persistent absence seizures, 13%-30% develop GTCS 
and 15% develop myoclonic seizures.
2,4
  Children with CAE are in the normal cognitive 
range, but when compared to matched controls without epilepsy, have significantly lower 
full IQ scores.
59
  In addition, they are more likely to have linguistic difficulties (43%) and 
a psychiatric diagnosis (61%), particularly attention-deficit/hyperactivity disorder 
(ADHD) and anxiety disorders compared to controls.
59
          
 
Benign Epilepsies  
Benign epilepsy is the most common type of seizures in children.  They are characterized 
by epileptic seizures that are easily treated, or require no treatment, and remit without 
sequelae.
3
  There are a number of syndromes that fall into this category: benign familiar 
neonatal seizures, benign infantile spasms, Panayiotopoulos syndrome (PS), benign 
childhood epilepsy with centrotemporal spikes (BECTS), and benign childhood occipital 
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epilepsy.  Table 3 summarizes the main features of the three idiopathic childhood focal 
epilepsies.   
 
Epidemiology  
Onset of BECTS is between 1-14 years, in 75% of patients, onset is between 7 and 10 
years, and there is a peak at 8-9 years.
60
  There is a male predominance of 1.5 times male 
compared to female.  Prevalence is around 15% in children with seizures aged 1-15 years.  
Incidence is 10-20 per 100,000 children aged 0-15 years.
61
  Age at onset for PS is 1-14 
years with a peak at 4-5 years.  In 75% of cases, onset occurs at 3-6 years of age.  
Prevalence is around 13% in children 3-6 years old with one or more non-febrile seizures 
and 6% in the 1-15 years old in those children with epilepsy.
2,60
  In the general 
population, 2-3 per 1,000 children may be affected.  Childhood occipital epilepsy 
(Gastaut type) is a rare condition with a prevalence of 0.2%-0.9% of all epilepsies, and 
2%-7% of benign childhood epilepsies.
4,60
  It is estimated to account for 0.15% of all 
focal epilepsies in childhood.  Age at onset is 3-15 years with a mean around 8 years of 
age.
4,60
       
 
The benign epilepsies have an unknown etiology, but suggested to be most likely genetic.  
Linkage to chromosome 15q14 has been suggested for BECTS, but not confirmed in 
several studies.
2,4,60,62
  Prevalence of febrile seizures is common in all benign epilepsies: 
10-25% in BECTS, 16-45% in PS, and 14% in childhood occipital epilepsy.
2,4,60,61
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Table 3: Comparison of Clinical Features of Three Idiopathic Childhood Focal 
Epilepsies 
 Panayiotopoulos 
Syndrome 
BECTS 
(Rolandic 
Epilepsy) 
Childhood 
Occipital Epilepsy 
(Late-Onset, 
Gastaut Type) 
Prevalence among 
children  
1-15 years with febrile 
seizures, % 
 
 
6 
 
 
15 
 
 
1-2 
Mean age at onset 
(range), years 
4-5 (1-14) 8-9 (1-15) 8-9 (3-16) 
Sex prevalence, % 54 males 60 males 50 males 
Prognosis Excellent Excellent Uncertain 
 
Clinical Course 
Long-term prognosis is good in BECTS and PS with remission in over 90% of cases by 
age 12 for BECTS and 1-2 years after seizure onset for PS.
2,4,60
  Antiepileptic drug 
(AED) therapy is often not needed in these syndromes as one-third of patients have a 
single seizure and only 5-10% will have more than 10 in the case of PS.  The majority of 
patients have less than 10 seizures; 10-20% have a single seizure and 10-20% have 
frequent seizures, but these also remit with age.
60
  The prognosis for childhood occipital 
epilepsy is variable.  A majority (50-60%) of patients achieve remission within 2-4 years 
from onset.
2,4,60
  Seizures show a fairly good response to AEDs in more than 90% of 
patients.
2,4,60
   
 
1.4.4. Adolescence 
Juvenile Myoclonic Epilepsy 
Idiopathic generalized epilepsies (IGE) are a distinct group of epilepsy syndromes.  
Syndromes of idiopathic generalized epilepsies are differentiated on the basis of the 
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predominant seizure pattern and age of onset.  Juvenile myoclonic epilepsy (JME) is a 
common epilepsy syndrome characterized by myoclonic seizures with or without other 
seizure types that occurs in adolescence.  It represents approximately 10% of all 
epilepsies.   
 
Epidemiology and Etiology   
JME age of onset ranges from 8-36 years, with a peak onset between 12 and 18 years.
63,64
  
The incidence of JME is estimated to be 1 per 100,000 persons, with a prevalence of 0.1-
0.2 per 100,000.  The frequency of JME has been reported to be 5-10% of all epilepsies 
and 18-40% of IGE.
63,64
 
 
A number of genetic abnormalities have been implicated for JME.  Five Mendelian JME 
genes have been identified, namely, CACNB4 , CASR , GABRa1 , GABRD,  
and Myoclonin1/EFHC1.
65
  A few mutations, including the KCNQ potassium channels 
and the ClC-2 chloride channel have been suggested.
66
  In addition, three SNP alleles in 
BRD2, Cx-36, and ME2 and microdeletions in 15q13.3, 15q11.2, and 16p13.11 also 
contribute risk to JME.
65
  The inheritance of IGEs and specifically JME is complex as it 
does not follow a well-defined Mendelian pattern.   
 
Clinical Course 
The most unique feature of JME among IGEs is that it is not outgrown and requires 
lifelong treatment, as the rate of recurrence is very high after discontinuation of 
medication, even after a long remission.
67
 However, population-based studies have 
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reported medical and social outcomes of JME patients with a 20-65 years range of 
follow-up and suggest there is a possibility to become seizure free.
68-70
  In one study 
54.5% of patients became seizure-free and 22.2% discontinued AED treatment and 39% 
eventually stopped AEDs and became seizure free in another study.
69,70
    
 
1.5. SUMMARY 
This chapter gives a broad overview of childhood epilepsies.  It is estimated that the 
prevalence of lifetime epilepsy/seizure disorder for the US child population is 1% which 
is slightly higher than prior estimates.
2
  Further study is warranted for pathophysiologic 
processes contributing to the development of comorbid conditions and may provide clues 
to the etiology of seizures disorders.  This will advance the development of therapies that 
might be useful in these specific epilepsy syndromes.   
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CHAPTER 2: IMPACT OF DEVELOPMENT ON PHARMACOKINETICS 
AND PHARMACOTHERAPY IN CHILDHOOD EPILEPSY: EMPHASIS ON 
TOPIRAMATE 
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2.1 DEVELOPMENTAL PHARMACOKINETICS  
Pharmacotherapy for children is challenging because there is a lack of prescribing 
information.  Pathophysiologic differences between children and adults result in age-
related differences in PK and drug effect.  Changes in development and how this may 
affect PK properties of absorption, distribution, metabolism and excretion are 
summarized below.  
   
2.1.1 Absorption 
The rate and extent of gastrointestinal absorption is primarily dependent upon pH 
dependent passive diffusion and motility of the stomach and small intestine in addition to 
gastric contents, gastric emptying time, and absorbing surface.
71-73
  The pH of the 
stomach is between 6 and 8 at birth, decreases to around 2-3 within 48 hours after birth, 
returns to neutral over the next 24 hours, and remains that way for the next 10 days.
71,74
  
Then, it slowly declines again until it reaches adult values at about 20-30 months of age 
with the lower limit of adult values are achieved by approximately 3 months of age.
72,75
      
 
Gastric emptying is prolonged and erratic; it approaches adult values within the first 6-8 
months of life.
73,76
  Gastric emptying is prolonged in neonates following reduced motility 
and peristalsis.  In infants and children, intestinal transit time is reduced as a result of 
increased intestinal motility.
76,77
  In both neonates and infants, additional factors such as 
the relative immaturity of the intestinal mucosa, immature biliary function, high levels of 
β-glucuronidase activity and variable microbial colonization may also affect 
absorption.
71,72
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Rectal absorption is generally higher in newborns and infants consequent to efficient 
translocation across the rectal mucosa, but also reduced presystemic drug clearance due 
to immaturity of many drug metabolizing enzymes in the liver.
71,72
  In contrast to rectal 
absorption, intramuscular administration is erratic in the neonate given that the muscular 
blood flow is low, muscular contractions are irregular and there is an increased 
percentage of water per unit of muscle mass.
71,72
  In contrast, the intramuscular route is 
very efficient in infants given a relatively high blood flow and more muscular 
contraction.
71,72
  Developmental differences in drug absorption between neonates, infants 
and older children are summarized in Table 4.  
 
Table 4: Characteristics of Drug Absorption Physiology During Development 
 Newborns Infants Children 
Gastric emptying 
time 
Irregular Increased Slightly increased 
Gastric pH >4 4 – 2 Normal (2-3) 
Intestinal motility Reduced Increased Slightly increased 
Absorbing surface Reduced Normal Adult pattern 
Mucous thickness  Increased -- Adult pattern 
Microbial flora Colonization Adult pattern Adult pattern 
Biliary function Not fully developed Developed Adult pattern 
Muscular blood flow Reduced Increased Adult pattern 
Skin permeability Increased Increases Near adult pattern 
Direction of alteration given relative to expected normal adult pattern. 
Adapted from Morselli, 1983 and Kearns, 2008. 
 
2.1.2 Distribution 
During development, changes in body composition occur that can affect drug 
distribution.  These changes include total body water (TBW), extracellular water (ECW), 
and body fat.  The most dynamic changes occur in the first year of life with the exception 
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of body fat, which is reduced by approximately 50% between 10 and 20 years of life.
78
  
In general, TBW and extracellular water decrease with age and body fat increases with 
age.  The magnitude of the possible difference between a newborn and a child or an adult 
regarding the volume of distribution will depend on the physicochemical properties of the 
drug and on the maturational and physiopathological status of each patient.
72
  
 
Plasma protein binding is significantly reduced in newborns given these factors: reduced 
plasma albumin concentration associated with the presence of fetal albumin, lower 
concentration of plasma globulin, high plasma concentration of unconjugated bilirubin 
associated with an elevated plasma concentration of free fatty acids, and a relatively 
acidic blood pH.
72
  In infants, plasma protein binding of drugs continues to be reduced 
because of the lower albumin and globulin contents.  The amount of reduction is variable 
and in most cases values comparable to adult values are reached at 10-15 years of age.
72
  
Developmental differences in drug distribution between neonates, infants and older 
children are summarized in Table 5. 
 
Table 5: Characteristics of Disposition Physiology During Development  
 Newborns Infants Children 
Plasma albumin Reduced Near normal Near adult pattern 
Fetal albumin Present Absent Absent 
Total proteins Reduced Decreased Near adult pattern 
Globulin Reduced Decreased Near adult pattern 
Serum bilirubin Increased Normal Adult pattern 
Free fatty acids Increased Normal Adult pattern 
Blood pH <7.4 ~7.4 7.4 
Adipose tissue Scarce Reduced ---- 
Extracellular water Increased Increased Adult pattern 
Total body water Increased Increased Adult pattern 
Direction of alteration given relative to expected normal adult pattern. 
Adapted from Morselli, 1983 and Kearns, 2008. 
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2.1.3 Metabolism and Excretion 
The majority of elimination of drugs occurs through either renal or biliary excretion of 
the unchanged parent drug, hepatic biotransformation to metabolites, or a combination of 
both.  Age-related changes in drug metabolism and excretion are summarized in Table 6 
and Table 7.  At birth, the glomerular filtration rate (GFR) is approximately 40 
mL/min/1.73 m
2
 in the full-term neonate.  GFR  increases steadily to 50% to 75% of 
adult function by 6 months.
72,76
  Tubular secretion matures by 7 months to a year.  In 
addition, there is a glomerular/tubular imbalance, due to the more advance maturation 
stage of glomerular function.  Such an imbalance may persist up to 6 months of age.
72
  
Full maturation of renal function is attained by 1 year of age.  Knowledge of transporter 
proteins that participate in active renal excretion and reabsorption is limited.
76
  Data on 
biliary excretion during development has not been studied.  However, it is likely to be 
reduced in the early weeks of life.      
 
Table 6: Characteristics of Renal Excretion Physiology During Development 
Direction of alteration given relative to expected normal adult pattern. 
Adapted from Morselli, 1983 and Kearns, 2008. 
 
 Newborns Infants Children 
Glomerular filtration Reduced Normal Normal adult values 
Tubular secretion Reduced Near normal Normal 
Tubular resorption Reduced Near normal Normal 
Glomerular/tubular 
imbalance 
Present Present (6 months) Normal 
Proteins in filtrate Present (30%) Low to absent Normally absent 
Urinary pH Low ~Low Normal 
Kidney weight/body 
weight ratio 
Increased Increased Near adult values 
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In general, most of the enzymatic activities responsible for metabolic degradation of 
drugs are reduced in the neonate.
72
  Phase I reactions mainly involve oxidation, reduction, 
and hydrolysis.  The primary phase I enzymes of metabolism include the cytochrome 
P450 (CYP) enzymes.  The developmental patterns of the ontogeny of a number of 
important drug metabolizing enzymes have been described.
72
  For example, CYP2D6 is 
low to absent in the fetal liver but present at 1 week of age.  It has poor activity (20% of 
adult) by 1 month reaching adult levels by 12 months of age.  CYP2C19 and CYP2C9 are 
absent from the fetal liver.  There is low activity in the first 2-4 weeks of life with adult 
activity reached by approximately 6 months of age.  Activity may exceed adult levels 
during childhood and declines to adult levels after the conclusion of puberty.  CYP1A2 is 
not present in appreciable levels in human fetal liver.
76
  Adult levels are reached by 
approximately 4 months and exceeded in children at 1–2 years of age.76  Once again, 
adult activity is reached after puberty.  CYP3A7 is the fetal form of CYP3A4 which is 
functionally active (and inducible) during gestation.
76
  It disappears by 1–4 weeks of 
postnatal when CYP3A4 activity predominates, but remains present in approximately 5% 
of individuals.  CYP3A4 has extremely low activity at birth reaching approximately 30–
40% of adult activity by 1 month and full adult activity by 6 months.  The activity may 
exceed adult activity between 1–4 years of age, decreasing to adult levels after puberty.76 
 
Phase II biotransformation reactions generally are conjugation reactions catalyzed by 
transferases.  The major phase II enzymes are uridine diphosphate-
glucuronosyltransferases, sulfotransferases, N-acetyltransferases, glutathione S-
transferases and methyltransferases.  The ontogeny of UGT is isoform specific.  In 
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general, adult activity is reached by 6-24 months of age.
71,76
 Sulfotransferases is also 
isoform specific and appears to develop more rapidly than uridine diphosphate-
glucuronosyltransferases.  Activity for some isoforms may exceed adult levels during 
infancy and early childhood.
71,76
  
 
Table 7: Characteristics of Metabolism Physiology During Development 
 Newborns Infants Children 
Hepatic microsomal 
activities 
Reduced Increased Slightly increased 
Blood esterase activity Reduced Normal (by 12 months) Adult pattern 
UGT activity Reduced Increased Near adult pattern 
Protein gamma Absent Present Present 
Liver blood flow Reduced Increased Near adult pattern 
Synthetic reactions Reduced Increased ---- 
Liver weight/body 
weight ratio 
Increased Increased Slightly increased 
Direction of alteration given relative to expected normal adult pattern. 
Adapted from Morselli, 1983 and Kearns, 2008. 
 
2.2 PHARMACOTHERAPY 
Roughly 17 drugs are used to treat childhood epilepsies.  As topiramate is the focus of 
this dissertation, this section begins with a review of its PK, pharmacology, and use in 
clinical epilepsy.  Thereafter, all other drugs used as oral maintenance therapy are 
discussed.     
 
2.2.1 Topiramate  
TPM is a second-generation antiepileptic medication approved in 1996 for seizures.  It 
was later approved for migraine prophylaxis, and in 2012 for weight loss in combination 
with phentermine.   
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Physical-Chemical Properties 
TPM is 2,3:4,5-Di-O-isopropylidene-ß-D-fructopyranose sulfamate (Figure 3).  The 
molecular formula is C12H21NO8S and its molecular weight is 339.36.  TPM is a white 
crystalline powder with a bitter taste.
79
  It is most soluble in alkaline solutions containing 
sodium hydroxide or sodium phosphate and having a pH of 9 to 10 and is freely soluble 
in acetone, chloroform, dimethylsulfoxide, and ethanol.
79
  Its solubility in water is 9.8 
mg/mL.
79
  Its saturated solution has a pH of 6.3. 
 
 
 
 
 
 
Figure 3: Chemical Structure of Topiramate  
 
Indications  
TPM is approved for monotherapy in patients greater than 2 years of age with partial 
onset or primary generalized tonic-clonic seizures.
79
  It is also approved for adjunctive 
therapy for adults and pediatric patients (2-16 years of age) with partial onset seizures or 
primary generalized tonic-clonic seizures, and in patients greater than 2 years of age with 
seizures associated with Lennox-Gastaut Syndrome.
79
  TPM is approved for treatment for 
adults and adolescents 12 years or age and older for prophylaxis of migraine headaches.
79
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Pharmacology  
TPM has a broad spectrum of action, although the precise mechanisms for its 
anticonvulsant and migraine prophylaxis effects are unknown.  Preclinical studies have 
revealed four properties that may contribute to TPM’s efficacy for epilepsy and migraine 
prophylaxis.  At pharmacologically relevant concentrations, TPM blocks voltage-
dependent sodium channels, augments the activity of the neurotransmitter GABA at some 
subtypes of the GABAA receptor, antagonizes the AMPA and kainite subtype of 
glutamate receptor, and inhibits the carbonic anhydrase enzyme, specifically isozymes II 
and IV.
80
     
 
Neuroprotection 
Studies have demonstrated that TPM exhibits neuroprotective properties.  
Neuroprotection has been reported for topiramate in models of status epilepticus and 
cerebral ischemia (Summary in Table 8).
81-88
  A recent study has shown diminished 
apoptosis in the CA1 region and dentate gyrus of hippocampus using a 80 mg/kg/day 
dose of TPM.
82
  In another study, there was a reduction of neuronal cell loss in the high 
dose group (loading dose 50 mg/kg; maintenance dose 20 mg/kg/day).
86
  Liu et al studied 
the combination of memantine and topiramate for hypoxic-ischemia brain injury.  They 
found no elevated apoptosis (programmed cell death) in the cortex, hippocampus, 
thalamus, and striatum using a combination of memantine (loading dose 20 mg/kg; 
maintenance dose 1 mg/kg BID) and TPM (loading dose 40 mg/kg; maintenance dose 1 
mg/kg BID).  Follett et al. studied the protective effect of intraperitoneal doses of 10, 30, 
and 50 mg/kg of topiramate in a rat model of periventricular leukomalacia, or white 
36 
 
matter injury.
81
  Only the 30 mg/kg topiramate dose significantly attenuated lesion 
severity and motor deficits.
81
  In several models, topiramate has a dose-dependent effect 
on reducing neuronal damage when administered after injury.    
 
Table 8: Topiramate Neuroprotective Studies 
Study Injury Animal Dose (mg/kg) Result 
Kurul et al.
82
 Hyperoxia-
induced 
neurodegeneration 
Rat pups 80 mg/kg/day Diminished apoptosis 
in CA1 region and 
dentate gyrus of 
hippocampus 
Liu et at.
88
 Hypoxic-ischemia Rat pups Loading 40 
mg/kg; 
maintenance 
1 mg/kg  
Reduction of neuronal 
cell less in 
combination therapy 
Schubert et 
al.
86
 
Perinatal hypoxia-
ischemia  
Piglets  10 and 20 
mg/kg/day 
Reduction of neuronal 
cell loss in high dose 
animals 
Follett et al.
81
 Periventricular 
leukomalacia 
Rat pups 10, 30, or 50 30 mg/kg has 
protective effect on 
lesions  
Koh et al.
89
 Hypoxic induced 
seizures 
Rat pups 30 & NBQX Repeated dose 
prevents susceptibility 
to hippocampal injury 
Cha et al.
87
 Status epilepticus  Rats  80 mg/kg/day After 4 weeks of 
treatment no different 
in cell loss 
Lee et al.
83
 Global ischemia Gerbils  50, 100, or 
200 
100 and 200 mg/kg 
reduced neuronal 
damage 
Niebauer et 
al.
84
 
Status epilepticus Rats  20, 40, or 80 Reduced degeneration 
at all doses 
Yang et al.
85
  Cerebral ischemia Rats  20 or 40 Reduced infarct 
volume and deficit 
scores, dose dependent 
effect 
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Pharmacokinetics  
Absorption 
Absorption of TPM is rapid with peak plasma concentrations occurring 2 hours after oral 
administration.  Absorption is linear with dose.
80
   Administration of TPM with food 
decreases the rate of absorption but not the extent.  Food decreases the mean maximum 
concentration by approximately 10% and delays the mean time to maximum 
concentration by approximately 2 hours.
90
  Initial studies of investigational IV TPM in 
twenty adult patients and twelve healthy volunteers on oral TPM estimated the absolute 
bioavailability of TPM to be close to 100%.
91,92
   
 
Distribution 
Topiramate is 9-17% bound to plasma proteins, but exhibits saturable binding to carbonic 
anhydrase in the red blood cells (RBCs).
93
  The apparent volume of distribution is 0.6-0.8 
L/kg, which is similar to the distribution of total body water.
80
   
 
Metabolism and Excretion  
Twenty to 30% of topiramate is metabolized when administered in the absence of 
enzyme inducers.
94
  The exact enzymes involved in the biotransformation of TPM are 
unknown, but it appears to undergo CYP-mediated oxidation.
95
  Multiple metabolites are 
formed by hydroxylation, hydrolysis, and glucuronidation.
96
 Doose and Streeter state that 
the CL/F of topiramate was reduced by 22 % in “hepatically impaired patients” compared 
with healthy subjects with epilepsy.
97
  When topiramate is administered with an enzyme 
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inducer, up to 50% of the dose undergoes metabolism.
80,98,99
  Topiramate inhibits 
CYP2C19.
96
            
 
Approximately 70% of a topiramate dose is excreted unchanged in the urine.  The 
clearance of TPM is reduced significantly in patients with renal dysfunction.  In a study 
investigating the effect of renal dysfunction on TPM clearance, the clearance was 
reduced by 42% in patients with a creatinine clearance 30-69 ml/min and 54% in patients 
with a creatinine clearance less than 30 ml/min.
100
  Oral TPM clearance (CL/F) is 
approximately 1 L/hr to 2 L/hr when given alone.
90,101-103
  Studies have found clearance 
to be substantially higher and half-life to be lower in children than in adults.
104-106
   
 
TPM PK in children and adolescents was determined from a single-center, open-labeled 
outpatient trial of 18 patients.
107,108
  In patients 4-17 years old, clearance values were 54% 
greater in children when TPM was administered in the presence of enzyme-inducing 
drugs and 44% greater in the absence of enzyme-inducing drugs.  There are a limited 
number of reports describing the PK in infants under 2 years of age.  Studies in younger 
children (6 months-4 years) have found a plasma clearance slightly higher than that 
reported for children and adolescents.  Again the plasma clearance was higher in infants 
on concomitant enzyme-inducing AEDs than in those on non-enzyme-inducing 
AEDs.
104,105
  Mikaeloff et al studied the PK of TPM in 9 children aged 6 months to 2 
years with epilepsy.  This study showed the apparent oral clearance of TPM was higher in 
infants taking enzyme inducing AEDs (85.4 + 34.0 ml/h/kg) compared with those taking 
neutral AEDs (46.5 + 12.8 ml/h/kg).
104
  Similar studies have found clearance to be 
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substantially higher in infants (age 24-29 months) than in adults.
104,105
  Two small (N = 
40) studies have investigated oral TPM PK and safety in neonates with HIE.
109,110
  These 
studies examined the effect of hypothermia on oral TPM plasma concentrations over a 72 
hour period.  Babies were assigned to one of two core temperature (31°C vs. 33°C) 
protocols.  Greater than 50% of the patients also received phenobarbital.  These studies 
found the range of plasma TPM concentration to be between 1.5-20 mg/L for mild 
hypothermia and 7-30 mg/L for deep hypothermia. 
 
Half-Life 
When TPM is administered alone, the half-life is reported to be 30-80 hours.
90,92,102,111,112
  
When administered with enzyme inducers, the half-life decreases to 12-15 hours.
80,113,114
  
In children, studies have found half-life to be faster in infants than in adults (5-17 
hours).
104-106
  A summary of reported PK parameters for different age groups is presented 
in Table 9.
104-106,108,109,115,116
       
 
Table 9: PK Parameters as a Function of Age 
Age Group Clearance 
(mL/hr/kg) 
Volume of 
Distribution (L/kg) 
Half-Life (hr) 
Neonates 13 - 18 NC 29 - 49 
Infants 7 - 110 0.3 - 2.13 6 - 14  
Children (< 10 
years) 
20 – 213 NC 5 - 17 
Children (10 -17 
years) 
20 - 90 NC 5 - 17 
Adults 14 – 30 0.6 - 0.8 30 - 80 
NC: not calculated  
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Drug Interactions  
The potential for drug interactions is a concern when administering multiple medications.  
Topiramate does not significantly alter the metabolism of other AEDs, although its 
metabolism can be changed by enzyme-inducing drugs.  Several AEDs interfere with 
TPM metabolism through the CYP system.  When co-administered with carbamazepine, 
phenytoin or valproic acid, topiramate concentrations were decreased by 40%, 48% and 
17%, respectively.
98,117,118
  
 
Adverse Effects 
The most common adverse events associated with TPM are headache, dizziness, fatigue, 
somnolence, anorexia, insomnia, and hyperesthesia.  Adverse events that are likely to 
have been related to the carbonic anhydrase activity of TPM (e.g. paresthesia, changes in 
serum bicarbonate, kidney stones) are frequent (13-35%) but are not usually considered 
clinical relevant.  The most frequent adverse events during maintenance therapy were 
headache (20%), reduced appetite (11%), and weight loss (11%).
2
  
 
Topiramate Use in Children 
Seizure Disorders 
Monotherapy in Children with Partial-Onset and Generalized-Onset Seizures 
The conclusion that topiramate is effective as initial monotherapy in children 2 to <10 
years of age with partial onset or primary generalized tonic-clonic seizures was based on 
a pharmacometric bridging approach using data from the controlled epilepsy trials 
described in the topiramate product label.  This approach consisted of first showing a 
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similar exposure-response relationship between pediatric patients down to 2 years of age 
and adults when topiramate was given as adjunctive therapy.
79
  Similarity of exposure-
response was also demonstrated in pediatric patients ages 6 to <16 years and adults when 
topiramate was given as initial monotherapy.  Specific dosing in children 2 to <10 years 
of age was derived from simulations utilizing plasma exposure ranges observed in 
pediatric and adult patients treated with topiramate initial monotherapy.
79
 
 
Adjunctive Therapy in Children with Partial-Onset Seizures 
The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-
clonic seizures in patients 2 years old and older was established in a 20-week multicenter, 
randomized, double-blind, placebo-controlled trials, comparing a single dose of 
topiramate to placebo.
119
  Patients, aged 3 to 59 years, were randomized to topiramate 
(n=39) 175 mg, 225 mg, or 400 mg, or placebo (n=41).  Primary generalized tonic-clonic 
seizures decreased by 56.7% in the topiramate group versus the placebo group (p=0.019).  
A seizure reduction rate of at least 50% was experienced by 56% of the topiramate 
patients versus 20% of the placebo group (p=0.001).  For all generalized seizures, 
topiramate decreased the average monthly seizure rate by 42.1% versus 0.9% in the 
placebo group (p=0.003).      
 
Adjunctive Therapy in Patient with Lennox-Gastaut Syndrome 
The effectiveness of topiramate as an adjunctive treatment for seizures associated with 
Lennox-Gastaut syndrome was established in a multicenter, randomized, double-blind, 
placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 
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2 years of age and older.  Adjunctive topiramate therapy was effective in reducing the 
number of drop attacks or tonic-atonic seizures associated with LGS.
120
  The median 
percentage reduction in drop attacks from baseline in the average monthly seizure rate 
was significantly greater in the topiramate group as compared to the placebo group 
(14.8% versus 5.1%, p=0.041).  Thirty-three percent of subjects in the topiramate group 
had a 50% reduction in tonic-clonic seizures as well as drop attacks (p=0.002, compared 
to placebo).   
 
Therapy in Patients with Infantile Spasms 
TPM’s efficacy against infantile spasms has been reported in at least 10 open-label 
trials.
2,121-130
  Twenty patients with infantile spasms were treated with TPM monotherapy 
and 30% became spasm free.
125
  In a prospective open-label study using TPM as initial 
therapy in 54 patients found that 57% of patients were seizure free for more than 24 
months.
130
  A prospective study in 40 children found 67.5% of all patients comprising 10 
patients treated with TPM monotherapy and 17 with the combination of TPM and ACTH 
became seizure-free.
131
  Greater than 75% reduction in the frequency of spasms was 
found in 4 of all patients and at least 50% reduction in 4 patients.
131
  In the most recent 
study, fifty children with the mean age of 9.4±3.8 months were evaluated.
132
  Cessation 
of all spasms occurred in 12 (48%) infants in TPM group and 4 (16%) in nitrazepam 
group.  Eight (32%) children in the TPM group and 7 (28%) in the nitrazepam group had 
more than 50% reduction in spasms frequency.
132
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Therapy in Patients with Dravet Syndrome 
Four open-labeled studies have examined TPM’s efficacy for children with severe 
myoclonic epilepsy in infancy (Dravet Syndrome).
123,126,133,134
  These studies showed that 
17% of the patients became seizure free, and 56% had a reduction greater than 50% in 
seizure frequency (mean 11.2 months, with a range of 2-24 months).  No patient 
experienced worsening of seizures with TPM therapy.
133
  In a subset of a study, 3 of 5 
Dravet patients responded to TPM therapy.
126
  Additionally, in a prospective study of 
TPM 2 of 6 patients with Dravet’s responded, but none became seizure-free.123     
 
Adjunctive Therapy in Patients with Juvenile Myoclonic Epilepsy 
TPM may have a role in treating JME although it seems to be more effective in 
controlling primary generalized tonic-clonic seizures and has low effect in controlling 
absences or myoclonic jerks.
119,135,136
  A posthoc analysis of two multicenter, double-
blind, randomized, placebo-controlled, trials of TPM for GTC seizures of nonfocal origin 
revealed that 22 patients with JME had been randomized to either TPM or placebo.  A 
significantly higher number of patients in the TPM-treated arm experienced a reduction 
of 50% or greater in GTC seizures compared to the placebo arm.
135
  The reductions of 
myoclonic and absence seizures were higher in the TPM arm, but the difference did not 
reach statistical significance.
135
   
 
 
 
 
44 
 
Adjunctive Therapy in Patients with Other Epilepsy Syndromes 
There are several small open-labeled add-on studies suggesting that TPM is effective for 
absence epilepsy (N=5)
137
, Doose syndrome (N=4)
126
, and progressive myoclonic 
epilepsies (N=8)
138
.  
 
Previously Reported Population PK Models 
Several population models for TPM have been reported in the literature.  These models 
are displayed in Table 10.  The populations explored in these models ranged from 6 
months of age up to 85 years old.  These models were both one- and two-compartment 
models and the covariates that were significant were age, enzyme inducing comedication, 
renal function, and weight.  
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Table 10: Topiramate Population Models in Literature  
Study Number 
of 
Subjects 
Population Model Covariates Conclusion 
Vovk et 
al.
139
 
26 Age: 8-54 years 
 
One-compartment CBZ dose 
and age 
Clearance was 70% 
higher in patients 
co-treated with 
carbamazepine and 
was found to 
increase with 
patient age. 
Jovanovic 
et al.
140
 
78 Age: 19-67 years, 
Mono-or co-
therapy 
One-compartment  
with first-order 
absorption and 
elimination 
CBZ dose, 
renal 
function 
Individualization 
for patients on 
different CBZ 
dosing regimen 
Bouillon-
Pichault 
et al.
141
 
22 Age: 6 months – 
2 years,  
One-compartment  
with first-order 
absorption and 
elimination with 
lag time 
Enzyme 
inducers on 
clearance and 
effect of BW 
and age on 
volume 
TPM dosage of 2-4 
mg/kg/day provided 
the AUC reported 
in adults 
Girgis et 
al
142
 
1,217  Age: 2-85 years Two-compartment  
with first-order 
absorption and 
elimination 
Weight, age, 
and 
concomitant 
AEDs 
No difference in 
PK-PD of TPM 
between adults and 
pediatric.   
Ahmed et 
al.
143
 
32 Age: 19-55 years, 
Healthy 
volunteers 
Two-compartment  
with first-order 
absorption and 
elimination 
Body weight PD study 
 
2.2.2 Other AEDs Useful in Treating Childhood Epilepsies  
Adrenocorticotropin and Steroids 
In the 1950s, the efficacy of adrenocorticotropin (ACTH) was first observed.
2,144
  A 
number of studies have reported the efficacy of corticosteroids in infantile spasms and 
confirmed the utility of ACTH in the treatment of this disorder.
2
  The epilepsy syndromes 
that respond uniquely to ACTH and corticosteroids therapy have an age-related onset 
during a critical period of brain development, as well as a characteristic regression or 
plateau of acquired milestones at seizure onset, and long-term cognitive impairment.    
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However, there are no clinical trials that compared the effectiveness of ACTH or oral 
corticosteroids versus placebo in controlling infantile spasms.  Two randomized control 
trials revealed that ACTH was superior to prednisone in spasm cessation.  When 
compared to vigabatrin, ACTH results in a higher and faster response rate in spasm 
control, with similar cognitive development after 9-44 months of treatment.
2,4
  Thus, 
ACTH may be considered for initial monotherapy of infantile spasms, while oral 
corticosteroids may be considered as alternative first-line therapy.
2,144
  In addition, a few 
studies have reported the use of ACTH for the treatment of myoclonic seizures and LGS 
with variable response rates.
145-147
 
 
Mechanism of Action 
The pathogenesis of infantile spasms, and therefore the mechanism of action of ACTH 
and steroids in this condition, is unknown, principally because there were no good animal 
models.  However, a number of promising animal models have now been developed.  The 
models currently used are either based on a specific cause of infantile spasms, such as 
loss of interneurons (aristaless-related homeobox ARX mouse), or propose a final 
common pathway underlying all causes of infantile spasms.
148
  Recently developed 
models are the ARX-linked aristaless-related knockout and knock-in mouse model, the 
multiple-hit model, corticotrophin-releasing hormone model, the NMDA model and the 
tetradotoxin model.
148
  No single model will replicate the human seizure exactly.  
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Various explanatory hypotheses have been formulated for the mechanism of action which 
have been discussed in detail by O’Regan and Brown.147  These include the correction of 
deficient or dysfunctional enzymes or enzyme systems, changes in intracellular-
extracellular electrolyte ratios, correction of hypoglycemia or low intracellular glucose, 
reduction in cerebral water content, an anti-inflammatory action, and immune modulation 
or suppression. 
 
Adverse Effects 
ACTH and steroids may cause significant side effects, including irritability, the 
development of Cushing syndrome, electrolyte disturbances (specifically hypokalemia), 
hyperglycemia, glucose intolerance, osteoporosis, infections, hypertension, and a usually 
reversible dilatation of the ventricular and extra-ventricular cerebrospinal fluid 
spaces.
149,150
  However, the more serious side effects have been reported predominantly 
with ACTH rather than prednisolone and have included severe sepsis resulting in 
death
150,151
 and cardiac hypertrophy.
152,153
  
 
Finally, the long term use of steroids (over many months) to maintain any initial benefit 
or to try and modify any underlying and potentially evolving progressive disorder may be 
complicated by immunosuppression, glucose intolerance, and osteoporosis.
149
  
 
Benzodiazepines 
Benzodiazepines are a class of drugs that enhance the effect of the neurotransmitter 
GABA at the GABAA receptor, resulting in sedative, hypnotic, anxiolytic, 
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anticonvulsant, and muscle relaxant properties.  Their high lipid solubility results in rapid 
central nervous system penetration and they are particularly useful as first-line agents in 
the management of status epilepticus and seizures.  There are a number of 
benzodiazepines that include diazepam, lorazepam, midazolam, clonazepam, nitrazepam, 
clorazepate, and clobazam.  The general mechanism of action and adverse effects are 
described here.  
 
Mechanism of Action 
Benzodiazepines augment inhibitory neurotransmission by enhancing the activity of 
GABA at the GABAA receptor.
2,144
  When GABA binds to the GABAA receptor, it 
increases the opening of the chloride ion channel, which results in hyperpolarization of 
the membrane and reduction in neuronal firing.
2,144
  Benzodiazepines do not activate the 
receptor directly but modulate GABA binding and enhance its effect by increasing the 
frequency of chloride ion channel opening.  This increases the inhibitory tone at GABA 
synapses, which limits neuronal firing and results in reduced seizure activity.
2,144
 
 
Adverse Effects 
Respiratory and cardiovascular depression are the most common adverse effect of 
benzodiazepines.
2
  Chronic treatment may be associated with sedation, fatigue, ataxia, 
cognitive dysfunction, drooling, and exacerbation of seizures.
2
  Treatment should not be 
abruptly stopped as it may lead to withdrawal symptoms.   
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Long-term treatment of benzodiazepines can result in tolerance (when a subject's reaction 
to a specific drug and concentration of the drug is progressively reduced, requiring an 
increase in concentration to achieve the desired effect).  Tolerance to one benzodiazepine 
does not necessarily result in tolerance to the others.  The mechanism underlying 
tolerance is not clear but may involve down-regulation of GABAA receptors, altered 
postsynaptic sensitivity to GABA, or modification in the expression of genes that encode 
for the various GABAA receptor subunits.
154
  
 
Carbamazepine 
Carbamazepine (CBZ) is an iminodibenzyl derivative, structurally similar to the tricyclic 
antidepressants.  CBZ is an effective treatment of epilepsy for partial and secondarily 
generalized seizures.  It is extensively metabolized in the liver, with approximately 1% of 
the administered dose excreted in the unchanged form.  The main oxidative pathway 
involves the formation of an active metabolite, carbamazepine- 10,11-epoxide, which 
possesses anticonvulsant properties similar to those of CBZ.
155
 
 
Mechanism of Action 
The main molecular mechanism of antiepileptic action of CBZ involves blocking voltage 
dependent sodium ion channels in cell membranes.
156
  It stabilizes the inactivated state of 
voltage-gated sodium channels, making fewer of these channels available to subsequently 
open.  This leaves the affected cells less excitable until the drug dissociates.  CBZ has 
also been shown to potentiate GABA receptors made up of alpha1, beta2, and gamma2 
subunits.
155
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Adverse Effects 
Overall, CBZ is generally well tolerated.  Short-term treatment adverse effects that have 
been reported include sedation, ataxia, dizziness, nausea, vomiting, constipation and 
diarrhea.  Long-term treatment with CBZ may modify plasma lipids, change the 
concentration of sex hormones, produce hyponatremia, increase appetite and cause 
weight-gain, reduce the number of white blood cells and induce several allergic 
reactions.
157
 
 
PK drug interactions involve both CBZ metabolism and CBZ binding to serum proteins.  
CBZ not only induces the capacity of CYP3A4 to enhance its own metabolism, but 
increases this enzyme system’s capacity to metabolism endogenous molecules and 
numerous drugs that are biotransformed through this mechanism.
156
  Depending on the 
concomitant medication, CBZ plasma concentration will be increased or decreased.  
Further details of the known interaction are available elsewhere.
2,144
 
 
Ethosuximide 
Ethosuximide is a succinimide anticonvulsant that is used mainly for absence seizures 
particularly when more effective agents fail or are not tolerated.  Other seizure types that 
may be favorably influenced by ethosuximide include atypical absence and myoclonic 
seizures.
2
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Mechanism of Action 
The mechanism of action of ethosuximide has not been identified.  However, the 
hypothesis is that ethosuximide blocks thalamic ’T’ type calcium channels, an effect 
possessed by drugs that are effective against absence seizures.
156
  Ethosuximide either 
reduces the number or the conductance of these channels.
2
  Other studies in 
thalamocortical neurons of rats have demonstrated an inhibitory effect of ethosuximide 
on non-inactivating sodium currents and on calcium-dependent potassium channels, but 
not on “T” calcium channels.2  
 
Adverse Effects 
Ethosuximide is relatively safe and effective.  Skin rashes and allergic and hypersensitive 
reactions are not common.
156
  Gastrointestinal side effects are the most common adverse 
reaction.  They include mostly abdominal discomfort, vomiting, diarrhea, and hiccups.  
Overdose may cause sedation and altered behavior.  Little information is available 
regarding the drug’s teratogenicity.  Ethosuximide exhibits relatively few drug-drug 
interactions but enzyme-inducing drugs can increase the clearance of ethosuximide or 
valproate can inhibit the metabolism.
2
 
 
Felbamate 
After being approved felbamate was found to cause severe bone marrow and liver 
toxicity.  Given this toxicity, the main indication for felbamate currently is used as a third 
or fourth line therapy in children with Lennox-Gastaut syndrome and similar forms of 
epilepsy who failed to respond to other AEDs.
2,158
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Mechanism of Action 
Felbamate has been proposed to have a unique dual mechanism of action as a positive 
modulator of GABAA receptors and as a blocker of NMDA receptors, particularly 
isoforms containing the NR2B subunit.
159
  Felbamate has been shown to inhibit the 
NMDA-induced intracellular calcium currents.
2
  Although there is some evidence that 
felbamate affects the GABA receptor there are contradictory studies on the lack of effect 
on ligand binding to the GABAA receptor and potentiation of GABA responses at high 
felbamate concentrations.
2
     
 
Adverse Effects 
The most common side effects in children are anorexia, somnolence, insomnia, vomiting, 
and nausea.
158
  However, during the first year following approval it was revealed that 
felbamate was associated with a relatively high incidence of life-threatening side effects.  
These included aplastic anemia and hepatotoxicity.
2,4
  Aplastic anemia was not reported 
in any child younger than the age of 13 years.
2
 
 
Gabapentin 
Gabapentin (GBP) has approval for adjunctive therapy of partial seizures in children 3 
years of age or older.
2,144
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Mechanism of Action 
GBP was designed as a GABA analog, and some studies have suggested that it modulates 
the action of the GABA synthetic enzyme, glutamic acid decarboxylase (GAD) and the 
glutamate synthesizing enzyme, branched-chain amino acid transaminase, resulting in 
increased GABA synthesis.
159
  GBP increases non-synaptic GABA responses from 
neuronal tissues in vitro and increases GABA levels in brain.
159
  While GBP was not 
found to have significant effect on any calcium channel current subtype (T, N, or L), 
studies have demonstrated that the drug may act by binding to the alpha2delta1 subunit of 
the calcium channel presumably inhibiting excessive neurotransmitter release by 
interfering with calcium channel functional expression or trafficking.
2,159
 
 
Adverse Effects 
Adverse effects with GBP are uncommon in children but typical side effects are 
somnolence, dizziness, ataxia, fatigue, nystagmus, headache, tremor, diplopia, and nausea 
and vomiting.
2
  
 
Lamotrigine 
Lamotrigine (LTG) was approved in 1998 as adjunctive therapy in the treatment of 
partial seizures and patients with LGS > 2 years of age.
2,158
  It has since been approved 
for monotherapy adults (aged 16 years and older) with partial-onset seizures who are 
receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or 
valproate as the single antiepileptic drug (AED) and bipolar disorder.  
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Mechanism of Action 
LTG appears to have a broad-spectrum of action; however, the identified mechanisms do 
not fully explain its clinical effectiveness.  Studies have demonstrated the LTG blocks 
sodium channels, leading to stabilization of neuronal membranes.
2
  It has also been 
suggested that LTG reduces the effects of glutamate on the rat’s spinal cord and reduced 
GABA receptor-mediated neurotransmission in rat amygdala, suggesting that a 
GABAergic mechanism may also be involved.
2,160
    
 
Adverse Effects 
The toxicity profile of LTG includes common adverse events seen with other AEDs, 
including dizziness, diplopia, headache, ataxia, blurred vision, nausea, somnolence, and 
vomiting.
2
  The FDA carries a black-box warning for severe skin rashes, and in clinical 
trials, serious rashes resembling Stevens-Johnson syndrome occurred in about 1 in 300 
adults and 1 in 100 children.
158
  
 
Levetiracetam 
Levetiracetam (LEV) is an anticonvulsant medication available since 2000 and is 
indications include monotherapy and as add-on therapy in partial-onset seizures as well 
as in patients with idiopathic generalized epilepsy for myoclonic and generalized tonic-
clonic seizures in adults and children > 4 years of age.
161
  It is widely used in patients 
younger than 4 years as monotherapy and in other epilepsy types.
2,144
  It has been shown 
to have good efficacy and an excellent safety profile in adults and older children.   
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Mechanism of Action 
The exact mechanisms of action of LEV are not completely understood.  It is thought the 
drug binds with high affinity to the synaptic vesicle protein SV2A, a protein thought to be 
involved in the regulation of synaptic vesicle fusion, exocytosis, and neurotransmitter 
release.
161
  LEV alters epileptiform burst ﬁring but not normal neuronal excitability.161   
 
Adverse Effects 
LEV is a popular choice for pediatric epilepsy given that it has no known interaction with 
other AEDs and is well tolerated.  The most common adverse events reported were 
headache, infection, anorexia, and somnolence.  However, occurrence of emergent 
behavioral side effects has been described.  Specifically, aggression, emotional liability, 
oppositional behavior, and psychosis has been described in some children.
2
 
 
Phenobarbital 
Phenobarbital (PB) is a barbiturate and one of the oldest anticonvulsants and sedatives, 
have been first synthesized in 1902.
162
  It has been useful in the management of severe 
and persistent seizures that do not response to more routine anticonvulsant therapy.
2,144
  It 
is the first-line treatment for neonatal seizures.
16
  Neonatologists use this drug because it 
is a well-known anticonvulsant available as injectable formulation and has been standard 
of care for decades.    
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Mechanism of Action 
Barbiturates enhance GABA-mediated inhibitory synaptic transmission on GABAA 
receptors.
163
  Current views suggest the phenobarbital modulates the postsynaptic effect 
of certain neurotransmitters.  The modulation is thought to affect both the inhibitory 
substance GABA and excitatory amino acids such as glutamate.
2
  
 
Adverse Effects 
The most frequently encountered adverse effects are sedation, disturbance of mood and 
behavior (excitement, irritability, aggression, or confusion) and induction of hepatic 
metabolism.
2,144
  Changes in metabolism can have an effect on the disposition of a wide 
variety of other drugs.  In addition to frequent adverse effects, phenobarbital can cause 
serious adverse effects and interact with other medications administered in the neonatal 
intensive care unit (NICU).
164
  It has been shown to induce apoptosis and cellular 
reorganization in neonate animals at concentrations obtained with clinical use in 
babies.
165,166
  It is also suggested that phenobarbital can inhibit cell proliferation by over 
60% in animal models.
166
  Exacerbation of seizures may occur with discontinuation of 
phenobarbital maintenance therapy.  
 
Phenytoin 
Phenytoin (PHT) is also an older anticonvulsant with FDA approval in 1939.  It has been 
shown to be effective for status epilepticus, partial seizures, tonic seizures, partial 
seizures secondarily generalized, and generalized tonic-clonic seizures.
2,144
  PHT is 
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widely used to treat neonatal seizures.
16
  It was shown to provide effective treatment for 
epilepsy without causing sedation, a major advantage over phenobarbital.
156
  
 
Mechanism of Action 
PHT has been suggested to act by reducing electrical conductance among brain cells by 
stabilizing the inactive state of voltage-gated sodium channels and delaying its rate of 
recovery from inactivation.
156,163
  This will block frequency, use, and voltage-dependent 
neuronal sodium channels, thus limiting the repetitive firing of action potentials.     
 
Adverse Effects 
PHT can affect the central nervous system and can include nystagmus, incoordination, 
and ataxia.  Somnolence and mood changes, nausea, extrapyramidal abnormalities, 
cerebello-vestibular toxicity, and mental changes have been reported.
156
  Similar to 
phenobarbital, phenytoin can induce apoptosis, inhibit cell proliferation, and cellular 
reorganization in neonate animals.
165,166
  Rarely, skin rashes, hypersensitivity, lymphoma, 
and hepatotoxicity have been reported.
156
    
 
Valproate 
Valproic acid (VPA) was approved in 1978 for monotherapy and adjunctive therapy of 
complex partial seizures and simple and complex absence seizures.  It rapidly became the 
drug of choice because it was the first drug with a broad spectrum of activity against 
different seizure types.
156
  It is indicated for monotherapy and adjunctive therapy in the 
treatment of patients with complex partial seizures and absence seizures.  VPA has found 
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some effectiveness in the treatment of partial seizures, LGS, infantile spasms, neonatal 
seizures, and febrile seizures.
2,144
 
 
Mechanism of Action 
The precise mechanism of action for antiepileptic effect is unknown.  VPA increases the 
brain GABAergic, inhibitory activity.
2,156
  In addition, VPA reduces cortical excitability 
by reducing sustained repetitive high-frequency firing by blocking voltage-sensitive 
sodium channels or by activating calcium-dependent potassium conductance.
2,156
  
 
Adverse Effects 
Gastrointestinal effects, hair loss, and weight gain have been reported, but much more 
important is the finding of teratogenicity associated with valproate which is dose-
dependent and may be associated with severe birth defects, such as spina bifida, cardiac 
abnormalities, skeletal, and renal malformations, as well as a decline in cognition, IQ, 
language, and possible autism.
156
  Severe hepatotoxicity has also been reported and 
children younger than 2 years old are at a higher risk.  In addition, there is an increased 
risk of liver failure and death from liver failure in patients who have a genetic liver 
problem caused by mitochondrial disorder.   
 
Marijuana 
The use of medical marijuana for childhood epilepsies has gained popularity in the recent 
years.  There are three compounds that have been isolated and identified as the most 
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potent: D9 -tetrahydrocannabinol (THC), cannabidiol (CBD) and cannibinol.  CBD is the 
non-psychotropic compound which has shown promise as an anticonvulsant.
167
  
 
Only two small (N=20) double-blinded, placebo-controlled studies of cannabinoids in 
epilepsy have been published.
167
  In both studies, daily oral CBD was used as an adjunct 
to antiepileptic drugs.  One study demonstrated a beneficial effect in seven out of eight 
patients, while the other showed no improvement in 12 patients.
167
  A Cochrane database 
review concluded that no reliable conclusions could be drawn regarding the efficacy of 
cannabinoids as a treatment for epilepsy.
168
  
 
Mechanism of Action 
CBD interacts with many non-endocannabinoid signaling pathways.  It is a blocker of the 
equilibrative nucleoside transporter (ENT), the orphan G-protein-coupled receptor 
GPR55, and the transient receptor potential of melastatin type 8 channel.
169
  CBD also 
enhances the activity of the 5-HT receptor, the alpha3 and alpha1 glycine receptors, the 
transient receptor potential of ankyrin type 1 channel, and has a bidirectional effect on 
intracellular calcium.
169
  Its precise anticonvulsant mechanism is unknown.     
 
Adverse Effects 
Multiple small studies of CBD safety in humans in both placebo-controlled and open 
trials have demonstrated that is well tolerated across a wide dosage range.  No significant 
central nervous system side effects were seen in acute and chronic administration.
169
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These studies were completed in adults and the toxicity in children is not well 
understood.  
 
2.3 OTHER THERAPIES 
2.3.1 The Ketogenic Diet 
The ketogenic diet (KD) is a high-fat, adequate-protein, low-carbohydrate regimen that is 
used primarily to treat refractory epilepsy in children.  The primary indications for KD is 
first-line therapy for the treatment of seizures in association with glucose transporter 
protein deficiency and pyruvate dehydrogenase deficiency.
2
  KD may be an alternative 
treatment, usually after the failure of valproate, for generalized epilepsies, particularly 
those with myoclonic seizures, including Dravet syndrome and Doose syndrome.
2,170
 
 
Mechanism of Action 
The production of ketone bodies from the oxidation of fat is the primary source of 
metabolic energy, which appears to be involved in the control of seizures.
171
  A recent 
review discussed in detail the neurochemical mechanisms of the KD that have been 
studied, although, the mechanism on anticonvulsant effect is unclear.  Ketone bodies 
derive from the metabolism of nonesterified fatty acids.  They are released from adipose 
tissue in response to a decrease in blood glucose, such as that which occurs during 
fasting.
171 
 
Similar mechanisms are involved in the KD, during which long-chain fatty acids are 
metabolized in the liver and converted into ketone bodies.  These fatty acids are oxidized 
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in the mitochondria, producing high levels of acetyl-CoA, which cannot be oxidized in 
the Krebs cycle.  The excess acetyl-CoA is converted to acetoacetate and subsequently to 
acetone and β-hydroxybutyrate.171  The ketone bodies cross the blood-brain barrier and 
are transported by monocarboxylic acid transporters to the brain interstitial space, the glia 
and the neurons.  In these tissues, the ketone bodies act as substrates in the Krebs cycle 
and respiratory chain, contributing to brain energy metabolism.
171
 
 
The implication of these mechanisms is that glycolysis and glucose flux are reduced, 
tricarboxylic acid cycle is increased, and cerebral energy reserves are increased.
2
  These 
biochemical changes appear to favor cerebral energetics and lead to increased resistance 
to seizures and a possible favorable cognitive effect.
2
   
 
Adverse Effects 
The diet can cause nausea and vomiting, fatigue, loss of appetite, and hypoglycemia.
2,172
  
Severe adverse effects are pancreatitis, death, and coma.  Some long-term effects that 
have been reported of the diet include kidney stones, skeletal fractures, and slow growth. 
(grosebeck, 2006, developmental medicine and child neurology).      
 
Modified Atkins Diet for Seizures 
In addition to KD, a modified Atkins diet can be used for intractable epilepsy.  It is 
similar to the KD in there is a higher proportion of fat and a lower proportion of 
carbohydrates compared with that in regular diets.  The use of the Atkins diet has not 
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been well studied.  A study evaluated the use of this diet in 20 patients and it was shown 
to be effective and well tolerated.
2
   
 
2.3.2 Surgery 
Surgical treatment is used for children with medically resistant seizures.
2
  This treatment 
involves removal of an area of the brain with an aim of alleviating seizures.  This can be 
applied to various brain structures or to cranial nerves.  Extensive evaluation needs to be 
determined whether seizure onset can be localized and to establish intractability.  Surgery 
does not need to be considered a last resort as the rate of cognitive and behavioral 
comorbidity associated with early onset of epilepsy is a high and early cessation of 
seizures likely leads to improved neurobehavioral outcomes.  In a recent Monte Carlo 
simulation using parameter from the literature epilepsy surgery yielded a higher life 
expectancy than continued medical treatment for surgically eligible children.
173
 
 
Surgical resection is offered to suitable candidates with drug-resistant focal epilepsy, 
about half will have long-term postoperative freedom from seizures.
174
  The goal for 
respective epilepsy surgery is the identification and accurate localization of the 
epileptogenic zone.  The history of disabling medically refractory focal seizures needs to 
be clearly established, which requires at least a good description of seizure semiology, 
repeated interictal EEG data, and an optimal MRI scan before consideration for surgical 
treatment.
4
  MRI is the choice for evaluating pediatric epilepsy surgery candidates but 
functional imaging, PET, MRS, single-photon emission computerized tomography, and 
fMRI each have their place in identifying dysfunctional cortical regions.  An additional 
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aspect of presurgical evaluation is extensive EEG recordings and neurobehavioral 
assessments.   
 
Epilepsy surgery has an important role in the treatment of pharmacoresistant epilepsy.  It 
should be considered on a case by case basis and after careful evaluation.   
 
2.3.3 Therapeutic Hypothermia 
Therapeutic hypothermia was first used in the 1950s to prevent ischemic brain injury 
during cardiac surgery and its use has increased to include various neurological 
conditions, including traumatic brain injury, stroke, and anoxic brain injury resulting 
from cardiac arrest.
175,176
  It is a common treatment for neonatal seizures.  Therapeutic 
hypothermia is thought to be neuroprotective and reduce brain injury.  It reduces cerebral 
metabolic rate and oxygen demand thereby decreasing cerebral edema and an intracranial 
pressure which helps preserve integrity of blood brain barrier by stabilizing lipoprotein 
membranes.
177
   
 
The discussion of therapeutic hypothermia is relevant to this thesis as it is a common 
treatment for neonatal seizures.  If a DBS assay is used for TDM or defining PK 
parameters in neonates, it will be useful to know how therapeutic hypothermia will affect 
physiology and pharmacokinetic parameters.  
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Definition and Methods of Hypothermia  
Body temperature is usually maintained near a constant level of around 37°C.  
Hypothermia is when the core body temperature drops below the required temperature for 
normal metabolism and body functions which is defined as 35°C.  Therapeutic 
hypothermia is a medical treatment that lowers a patient’s body temperature in order to 
help reduce the risk of ischemic injury to tissue following a period of insufficient blood 
flow.  Therapeutic hypothermia has been defined into three categories, depending on 
depth of cooling: mild, moderate, and deep (Table 11).
178
   
 
Table 11:  Categories of Therapeutic Hypothermia 
Category  Core Temperature (°C) Group 
Mild 32-35 Adults, children, and neonates 
Moderate 28-32 Adults, children, and neonates 
Deep <28 Neonates 
 
The medical methods by which hypothermia is induced falls into two categories: invasive 
and non-invasive.  Invasive methods could include cold IV infusion or cooling catheters 
while non-invasive would be cooling blankets or fans.  Cooling catheters are inserted into 
the femoral vein.  Cooled saline solution is then circulated through the body and cools the 
patient’s whole body by lowering the temperature of the patient’s blood.  Catheters 
reduce body temperature at rates ranging from 1.5°C - 4°C per hour.  Catheter-based 
temperature management has been shown to provide faster, more precise and more 
efficient cooling compared to all external methods, especially conventional.
179,180
  
Adverse events associated with cooling catheters include bleeding, infection, vascular 
puncture, and deep vein thrombosis.
181
  
65 
 
 
Cooling blankets or fans are an inexpensive and easy method for cooling patients.  
Cooling is slower than invasive methods at a range of 0.5°C - 1°C per hour.  For cooling 
blankets, cold water is circulated through a blanket wrapped around the torso or leg.  
Cooling blankets lower a patient’s temperature exclusively by cooling a patient’s skin 
and accordingly require no clinician performed invasive procedures.  Water blankets 
could overshoot the desired temperature, have slower induction time, increased 
compensatory response, and decreased patient access.  There are also a number of non-
invasive head cooling caps designed to target cooling at the brain.  These caps are filled 
with a coolant agent such as ice or gel.    
 
Animal and Human Studies 
In addition to physiological changes, new evidence from animal studies suggests 
hypothermia may be effective in various clinical situations.  Experiments have been 
conducted using different species, models, degrees and duration of cooling.  Post-hypoxic 
hypothermia has been shown to be neuroprotective in the neonatal rat, newborn pig, and 
near term fetal sheep.
182-184
  Based on these studies, cooling should last for 72 hours and 
cooling should start with a maximum delay of 5.5 h after birth.
185,186
 These observations 
have been confirmed by clinical studies.  
 
In two multi-center, randomized, controlled trials of hypothermia treatment increased the 
odds for survival and better outcomes in neonates treated with hypothermia (33°C).187,188  
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Whole-body hypothermia reduced the risk of death or disability in infants with moderate 
or severe HIE.
189
  Varies clinical trials have used  different methods of cooling (cooling 
fan, head cooling, whole-body cooling) and shown that each is effective in reaching the 
target rectal temperatures.   
 
Physiologic Changes 
Cardiovascular 
During hypothermia, there is a redistribution of blood away from the gastrointestinal 
tract, kidney, and liver towards coronary and cerebral circulation.  Blood flow to the 
organs reduces with progressive hypothermia.  The heart, liver and brain maintain a 
higher level of flow in comparison with the kidneys to 27°C.  However, at 25° to 20°C 
renal and myocardial blood flows are sustained at 20% to 25% of normothermic levels 
whereas cerebral and hepatic blood flow show greater decreases.
190,191
  
 
In neonates undergoing therapeutic hypothermia, heart rate drops by 14 to 45 beats per 
minute and returns to normal after rewarming.
189,192-194
  Cardiac output was also reduced 
by 33% and stroke volume by 23% in neonates undergoing moderate hypothermia.
195
  
For moderate hypothermia, there was no change in ECG, blood viscosity, or fibrillations 
when cooled to 33°C.   
 
Neurological  
Studies have suggested that cerebral blood flow is decreased in hypothermia.  
Specifically, cerebral blood flow decreased 5% for every 1°C in canines.
196
  In adult 
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animals and humans, EEG parameters of amplitude and frequency decrease at <32°C.  
However, one study evaluated whether core body temperature affected quantified EEG 
parameters during the rewarming phase of hypothermia treatment in neonates with HIE.  
They found that core body temperature had no significant effects on the EEG 
parameters.
197
  There is no evidence to suggest a difference in seizure incidence during 
hypothermia in either adults or neonates.  
   
Hematologic 
An association between abnormal bleeding and hypothermia is well documented in the 
literature.
198
  The coagulation cascade consists of a series of enzymatic reactions.  A 
research group demonstrated an increase in the activated partial thromboplastin time from 
a mean + SD of 36 + 0.7 seconds at 37°C to 46.1 + 1.1 seconds at 31°C in samples from 
10 volunteers.
199
  Hypothermia has been shown to inhibit platelet function.  An in vivo 
study found that thromboxane-A2 and thrombin-induced platelet aggregation were 
inhibited during hypothermia in healthy volunteers.
200
  Platelet dysfunction was reversed 
with rewarming.  Decreased platelet count was observed in 10 healthy volunteers during 
hypothermia.
199
  Mild thrombocytopenia was present in neonates at temperatures below 
35°C.
201
   In both adults and neonates these studies did not find an increase in bleeding 
time or hemorrhage.   
     
Endocrine and Metabolic 
As with a decreased blood flow, basal and cerebral metabolic rates are decreased during 
hypothermia.  In one study examining newborn swine, there was a 5-7% decrease for 
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every 1°C drop in body temperature.
202
  Decreased CO2 and O2 production have been 
observed during cooling.  There is also an increase in lipolysis.
203
  Hypothermia can 
cause hyperglycemia, which occurs rapidly with cooling, and it is associated with 
decreases in both pancreatic release of insulin and insulin sensitivity.
198
  Cooling results 
in increased gluconeogenesis and glycogenolysis, which may be due to a rise in 
circulating catecholamines and cortisol.
204
  Hyperglycemia has been associated with 
worse neurological outcomes.
205
  Frequent monitoring of glucose, lactate, and oxygen 
levels are particularly important during rewarming.   
 
Respiratory 
Blood gas values are affected by hypothermia because of increased solubility of gases at 
lower temperatures and reduced metabolic rate.
192
  The blood pH increases by 0.016 
points with every 1°C drop in core temperature while the CO2 partial pressure 
decreases.
192,206
  The oxyhemoglobin dissociation curve is shifted to the left at lower 
temperatures, resulting in a higher affinity of hemoglobin for oxygen.  The resulting 
decrease in oxygen release to tissues is counterbalanced by decreased tissue oxygen 
demand at lower temperatures.
207
  Pulmonary vascular resistance may increase at lower 
temperatures which are most likely due to vasoconstriction.  As with other body 
functions, the respiratory rate is decreased at lower temperatures.    
 
Renal Function and Electrolyte Levels 
Although animal models and studies in adults report alterations in renal perfusion and 
renal function during hypothermia, randomized clinical trials of hypothermia in neonates 
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with birth asphyxia have not found significant differences in urine output or 
creatinine.
192,201
  It is known that potassium moves into cells as temperature drops.  
Patients may experience mild hypokalemia.  Adults studies have suggested that there is 
increased electrolyte loss and hypomagnesaemia, hypocalcaemia, and hypophosphatemia 
can occur.
208
  No significant electrolyte disturbance have been reported in randomized 
clinical trials of neonates.
201
  
  
Musculoskeletal 
The body’s response to hypothermia will involve various mechanisms to generate heat.  
Changes in the musculoskeletal system start at just a 1°C drop in core temperature.
192
  
Shivering, the major musculoskeletal change occurs between core temperatures of 34 – 
36 °C and diminishes with core temperatures below 34°C.
198
  It is suggested that 
shivering occurs when the preoptic region of the hypothalamus is either cooled or reset to 
a higher baseline temperature.
209
  This activation results in an integrated series of 
responses that activates the α motor neurons in an involuntary, oscillatory muscular 
activity that augments metabolic heat production, resulting in increased body 
temperature.
198
   
 
Shivering has also been shown to increase the levels of norepinephrine and cortisol and 
increase the basal metabolic rate.
192
  This results in increases in oxygen consumption.  
These adverse effects cause stress on the body and can take away from the beneficial 
aspects of hypothermia.  Thus, administration of sedatives and analgesics is 
recommended to be given to patients undergoing therapeutic hypothermia.   
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Table 12: Physiologic Effects of Mild to Deep Hypothermia in Neonates 
Physiological Effect 
Cardiovascular Decreased heart rate 
Decreased cardiac output 
Vasoconstriction 
Increased blood pressure 
 
Endocrine Decreased insulin release and sensitivity 
Increased gluconeogenesis and glycogenolysis 
Increase in catechol and cortisol 
 
Hematologic Mild thrombocytopenia
 
Metabolic Decreased basal and cerebral metabolic rate 
Decreased CO2 and O2 production 
Increased lipolysis 
 
Neurologic Decreased cerebral blood flow 
Renal No change in urine output 
No change in electrolyte alterations  
 
Respiratory Increase blood pH  
Decreased respiratory rate 
Increase in pulmonary vascular resistance 
 
Pharmacologic Changes 
Pharmacokinetics 
Considerations for hypothermia therapy in neonates have not been well studied.  Few 
studies have examined the changes in drug disposition.  Table 13 summarizes 
pharmacologic changes during hypothermia.  Many PK parameters can be affected by 
hypothermia including absorption, distribution, elimination, and metabolism.   
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Table 13: Pharmacologic Effects of Mild to Deep Hypothermia  
Pharmacological  Effect 
Absorption Decreased gastrointestinal motility 
May cause prolonged time to reach maximum   
concentration 
 
Distribution Increased or decreased volume of 
distribution; affected by physiological factors 
Changes in protein binding capacity, lipid 
solubility, and tissue binding capacity 
 
Metabolism Decreased bile flow 
Decreased activity of active hepatobiliary 
transport 
Reduced enzyme metabolic activity 
Changes in binding pocket conformation 
Decreased rate of redox reactions  
Change in affinity of oxygen for ferric iron 
Changes in nicotinamide adenine 
dinucleotide phosphate P450 reductase 
activity 
Location of metabolic process 
Membrane fluidity 
 
Elimination Decreased renal perfusion 
Changes in tubular secretion and reabsorption 
unknown 
 
Pharmacodynamics Enzymatic inactivation or reduction  
Drug-target affinity 
Onset and recovery time of the effect 
 
 
Absorption  
Changes in absorption may cause prolonged time to reach maximum concentrations and 
decreased gastrointestinal motility.  These changes will be affected by physiological 
factors such as gastric and duodenal pH, acid dissociation constant (pKa), and lipid 
solubility.  If the therapy is given orally it may take longer to be effective.  The extent of 
absorption has not been studied.  
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Distribution 
Distribution can be decreased or increased depending on the physiochemical properties of 
the drug.  It will be affected by physiological factors such as blood perfusion and pH.  
Changes in these factors can change the protein binding capacity, lipid solubility and 
tissue binding capacity.  During hypothermia there is a redistribution of blood away from 
the GI tract, kidney, and liver towards coronary and cerebral circulations.  This could 
lead to more drugs crossing the blood brain barrier causing an enhanced cerebral effect.  
Drugs administered before, may be extensively distributed and remain stored in the 
tissues during hypothermia.  During rewarming, drugs may redistribute from tissues, 
leading to a rise in plasma levels that may have a clinical effect.  A study examined the 
effect of hypothermia on gentamicin in piglets.  The serum concentration of gentamicin 
was consistently higher during hypothermia than during normothermia.  Elimination half-
life was longer, volume of central compartment, volume of distribution, and total body 
clearance were significantly reduced during hypothermia.
210
  
 
Metabolism  
Bile flow and activity of active hepatobiliary transport decrease during hypothermia.  
Studies have examined hepatocyte enzymatic function and found reduced enzyme 
metabolic activity, changes in binding pocket conformation with reduced substrate 
affinity, decreased rate of redox reactions, changes in affinity of oxygen for ferric iron, 
location of metabolic process, and membrane fluidity.
211
  Studies in piglets and neonates 
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have shown increased plasma concentrations of fentanyl and morphine suggesting 
decreased CYP3A and UGT activity.
212,213
 
 
Elimination 
During hypothermia, renal elimination appears to decrease.  Nishida et al investigated 
phenolsulfonphtalein (PSP) disposition in male Wistar rats during hypothermia.  PSP, a 
hydrophilic dye used as a renal function test compound in humans, and is excreted into 
the bile and urine as a free form or conjugative metabolite in rats.
214
  The plasma 
disappearance of free PSP after IV administration was delayed in hypothermic rats.  Total 
clearance decreased to about 60% and 40% that of normothermic rats.
214
  The decrease in 
clearance was suggested to be due to decreased cardiac output.   
 
Pharmacodynamics 
Pharmacodynamic changes can also occur during hypothermia.  Enzymatic inactivation 
such as changes in EC50, drug-target affinity, and onset and recovery time of the effect 
could be affected.  One report described a 120% increase in the duration of action of 
vecuronium in hypothermic subjects compared to normothermic subjects.
215
   
 
2.4 SUMMARY AND RATIONALE FOR MY PROJECTS 
Topiramate has the potential to be an effective therapy for neonatal seizures and Dravet’s 
syndrome.  As has been discussed in this chapter, a limiting factor in the further 
development of TPM for these conditions is obtaining the necessary PK and 
pharmacodynamic information to design adequately controlled trials.  One major hurdle 
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in addressing this problem is the severe restriction on blood sampling in critically ill 
children, in whom blood is collected for a multitude of lab tests.  This circumstance 
reduces the blood volume available for pharmacology studies.  Consequently, the 
necessary research on PK and dose finding is often limited.   
 
One solution to this problem is the use of whole blood or DBS to measure drug 
concentrations in replace of plasma.  This approach reduces the volume of blood needed 
for a drug assay by greater than 50%.  Further complicating the use of whole blood for 
TPM measurements is the fact that the drug exhibits saturable binding to carbonic 
anhydrases in RBCs.  As a result, there is a non-linear relationship between whole blood 
and plasma, which complicates interpretation and comparison of TPM concentrations 
between matrices.
93
  If TPM is measured in whole blood without correction for non-linear 
binding this would result in inaccurate PK estimates.  For example, Filippi et al used 
DBS to measure TPM concentrations in neonates.
109
  Blood values were corrected by the 
hematocrit to obtain plasma values using an equation that assumed TPM is isolated in the 
plasma.  However, this equation doesn’t take into account the binding of TPM to 
carbonic anhydrase or TPM present in the RBCs.  This equation would result in 
concentrations higher than what would be seen if correcting for TPM binding to carbonic 
anhydrases. It is important to establish the relationship between whole blood and plasma 
concentrations due to the binding. With an improved assay we could quickly measure 
TPM concentrations in children while limiting the volume of blood that is collected.  
Thus, my thesis project characterized the relationship between whole blood or DBS and 
plasma to enable use of a DBS assay and method to account for the nonlinear binding to 
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provide a more accurate comparison of topiramate concentrations in whole blood to 
plasma concentration, which is the matrix typically measured in the clinic.  This will be 
important for clinical use and characterization of TPM’s disposition.  If TPM is measured 
in whole blood or DBS without correction for the non-linear binding, you will not be able 
to relate that concentration to a plasma concentration as it is not a one to one relationship. 
 
From September 2010 to May 2015, I conceptualized, managed, and coordinated the 
characterization of the relationship between whole blood and plasma TPM 
concentrations.  There are 3 components to my project with an overall objective of 
characterizing the relationship between plasma and whole blood topiramate 
concentrations for use in a clinical setting.   
 
2.4.1 Hypothesis and Specific Aims 
The overall hypothesis for this project is that a physiological-based equation will 
accurately estimate plasma concentrations based on a whole blood or DBS concentration.  
In order to characterize the processes necessary to determine an appropriate equation that 
can capture the relationship DBS, whole blood, and plasma assays were developed. To 
further examine the relationship between whole blood and plasma concentrations three 
studies were completed in dogs, adults, and pediatrics.     
 
Aim #1: Develop assays to measure TPM concentrations in DBS, whole blood, and 
plasma in a small volume of sample to accommodate the lower number of blood samples 
available in pediatric patients and animals. 
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Aim #2: Characterize the relationship between whole blood and plasma TPM 
concentrations and compare the PK of IV and oral TPM in plasma and whole blood in 
dogs with naturally-occurring epilepsy.  
 
Aim #3: Characterize the relationship between whole blood and plasma TPM 
concentrations in adults and children. 
 
2.4.2 My Role in Each Project 
Development of Bioanalytical Methods for Measurement of Topiramate Concentrations 
 Developed and validated an assay for measurement of TPM in whole blood, plasma, and 
DBS according to the recommended guidelines provided by the US Food and Drug 
Administration.
216
 
 
Whole Blood TPM Pharmacokinetics for Intravenous and Oral Dosing in Dogs with 
Naturally-Occurring Epilepsy 
 Performed LC-MS assay of topiramate in whole blood 
 Performed PK analysis of dog whole blood concentration-time data 
 Wrote final study report and manuscripts 
 
Comparison of Whole Blood and Plasma Assay Methods for Measurement of Topiramate 
Concentration in Adults 
 Designed the study and wrote the protocol 
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 Prepared applications and obtained IRB approval  
 Served as principal investigator and coordinator (recruited, screened, enrolled, and 
consented subjects) 
 Performed LC-MS assay of topiramate in whole blood, plasma, and DBS 
 Wrote final study report and manuscripts 
 
Comparison of Topiramate Concentrations in Whole Blood and Plasma in Children 
 Co-principal investigator and coordinator 
 Designed the study and wrote the protocol 
 Prepared applications and obtained IRB approval 
 Coordinated meetings and presented study to investigators at Gillette Children’s 
Specialty Healthcare, MINCEP, and Minnesota Epilepsy Group  
 Recruited subjects from Minnesota Epilepsy Group Clinic, MINCEP, and Gillette 
Children’s Specialty Healthcare 
 Wrote final study report and manuscripts 
  
78 
 
 
 
 
 
 
 
 
 
CHAPTER 3: DEVELOPMENT OF BIOANALYTICAL METHODS FOR 
MEASUREMENT OF TOPIRAMATE CONCENTRATIONS 
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3.1 INTRODUCTION 
AEDs are the mainstay for the control of seizures in the management of epilepsy.
217
  The 
goal of AED therapy is long-term seizure control with minimal or no side effects.  
However, fluctuations in AED concentrations may increase the risk of breakthrough 
seizures at lower plasma concentrations and adverse events may occur at peak plasma 
concentrations.
218,219
  In practice it is the patient who is treated and not the concentration.  
The dose of a drug is adjusted, using an individual’s drug concentration as a guide, to 
optimize a drug’s efficacy, avoid, minimize or identify toxicity, and detect or confirm 
poor compliance (Table 14).
220
   
 
It is therefore important to appreciate that therapeutic drug monitoring (TDM) begins 
before a drug concentration is measured and that the measurement itself is only part of 
the overall process of planning, monitoring, and optimally adjusting the dosage 
regiment.
220
  TDM can guide dosage adjustments and is especially useful for children due 
to the greater PK variability in this population compared to adults.
218
  TDM is also 
important in assessing compliance versus drug adherence with the prescribed 
regimen.
218,221,222
  Side effects in particular can lead to treatment non-adherence,
223,224
 a 
significant problem in patients with epilepsy with a prevalence as high as 40%.
225
  
Periods of poor adherence to AED therapy can result in undesirable clinical 
consequences, such as increased seizure occurrence and higher incidences of emergency 
department visits, hospital admissions, motor vehicle injuries, fractures, and death, when 
compared with periods of compliant dosing.
225-227
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There are two types of concentration ranges that can be defined for a compound.  First, 
the reference range can be defined as a range of a drug concentration, which specifies a 
lower limit below which a therapeutic response is unlikely to occur and an upper limit 
where toxicity is more likely to occur.  Second, the suggested therapeutic drug 
concentration range refers to a range of concentrations where a majority of the population 
is thought to experience efficacy with a low number of adverse events.  A reference range 
for TPM has been established (5-20 mcg/ml).
218
  In addition, one study has examined the 
therapeutic concentration response in sixty-five patients with refractory focal epilepsy.
219
  
They found optimal treatment response higher than 2 mcg/ml but no further increase in 
efficacy occurred at concentrations above 10.5 mcg/ml.
219
   
 
Table 14:  General indications for therapeutic drug monitoring
220
 
1. After initiation of treatment (to provide a baseline steady-state concentrations) 
2. After change in drug dosage, in particular when non-linear kinetics apply (to confirm 
new drug concentration) 
3. At therapeutic failure (to confirm or exclude a pharmacokinetic explanation for 
uncontrolled seizures or adverse events) 
4. To establish an individual therapeutic concentration range (when a person has 
attained the desired clinical outcome), which can be used subsequently to assess 
potential causes of change in response 
5. To identify or control for drug-drug interaction 
6. After a change in drug formulation (including generic substitution) 
7. To guide dosage adjustment in patients where potentially important pharmacokinetic 
changes are anticipated consequent to physiological or pathological changes (e.g. 
pregnancy, hepatic disease, renal disease, and gastrointestinal conditions)  
8. When poor drug adherence is suspected 
9. Suspected toxicity 
10. To guide dose adjustment for AEDs with dose-dependent pharmacokinetics 
11. An emergency situation (suspected overdose, status epilepticus) 
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3.2 BIOLOGICAL FLUIDS FOR DRUG MEASUREMENT 
AED concentrations are commonly measured in plasma or serum.  Concentrations are 
usually identical in these matrices, and most published data relate to concentrations in 
these fluids.
228
  There are a number of different matrices that can be used to measure drug 
levels including serum, plasma, saliva, whole blood, tears, urine, and cerebrospinal fluid.   
 
DBS is a technology that uses whole blood and has been used to determine drug 
concentration for preclinical and clinical studies.  It has been determined to be feasible 
for a wide range of compounds.  DBS technology has a number of advantages over 
conventional sample collection.  These include practical, clinical, and cost considerations.  
Use of DBS technology allows for less invasive sampling (finger or heel prick rather than 
a venipuncture) and as much as a 90% reduction in blood volume.  Use of DBS can 
simplify sample collection and make shipping of samples easier.  
 
A general guideline for blood collection in children used by many Institutional Review 
Boards (IRB) is a maximum of 3-5% of blood volume over a one to three month period 
for research purposes.
229
  This restriction leaves a limited amount of blood volume for PK 
studies.  A whole blood or DBS assay would be desired for drug monitoring in children 
and infants as the volume that can be collected is often limited.   
     
It is practical to measure drug concentrations in whole blood or DBS, but drug 
concentrations may not be identical in RBCs and plasma as the composition and 
complexity of the different matrices is significantly different from each other.
228,230
  The 
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nature and chemical properties of the drug can determine the matrix for measurement as 
some drugs may bind to different constituents in the blood.  Understanding the 
interactions between analyte and matrix aids in the decision of a suitable sample 
preparation technique.
230
  When working with whole blood or DBS samples, the 
distribution of the compound between RBCs and plasma, the enzymatic stability of the 
analyte in blood, and protein and RBC binding should be considered.
230
     
 
Analysis of whole blood data may be misleading if the concentration of drug differs 
between plasma and whole blood as a consequence of differential binding to a specific 
component in the blood.  In addition, the blood to plasma ratio determines the 
concentration of the drug in whole blood compared to plasma and provides an indication 
of drug binding to erythrocytes.  Knowledge of the RBC partitioning of topiramate into 
RBCs enables a rational choice of appropriate biological fluid and physiologically 
meaningful referencing of PK parameters of drugs to concentrations in whole blood, 
plasma, or DBS.   
 
3.3 SIGNIFICANCE AND AIMS OF CHAPTER 
The use of whole blood or plasma does not result in comparable TPM comcentrations.  
TPM exhibits saturable binding to carbonic anhydrase in RBCs and the use of DBS 
sample collection to measure this compound.
93
 TPM concentrations are expected to be 
higher in whole blood concentrations versus plasma concentrations, particularly at TPM 
concentrations near the lower limit of its reference range (5-20 mg/L).
218
  Thus, TDM of 
TPM using whole blood samples may mislead the clinician, who is accustomed to 
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receiving TPM concentrations measured in plasma samples.  The differences in whole 
blood concentrations may result in different PK parameter estimates. 
3.3.1 Aim 
The primary objective of this chapter is to develop an assay for measurement of TPM 
concentrations in whole blood and DBS.  
The specific aim of this project is to: 
Aim #1: Development of a sensitive method for measuring TPM concentrations in whole 
blood following DBS sample collection. 
3.4 TOPIRAMATE ASSAYS 
Several methods have been described to measure TPM in plasma or serum.
231-235
  Gas
chromatography tandem MS was used in the early development of TPM.
236,237
Fluorescence polarization immunoassay (FPIA) is another commonly used method.
238
FPIA is reportedly highly accurate and precise, but may be prone to interference from 
metabolites.
238
  LC-MS is a highly sensitive, accurate and precise method of quantitating
drugs and metabolites in biological fluids.  
Several LC-MS assays measuring TPM concentrations in plasma have been 
published.
231,239,240
  These methods use plasma volumes of 200-500 µL, which requires
sample blood volumes between 0.5 mL and 2 mL.  There have been three methods 
reported that use DBS as the biological sample to measure TPM with LC-MS.
241-243
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Evaluation of the relationship between whole blood and DBS with plasma has been 
reported.
93,243
  Shank and colleagues comparatively assessed TPM PK in 27 healthy male
subjects, based on plasma and whole blood data.  They found a lower oral clearance, 
apparent volume of distribution, and longer half-life in whole blood compared to 
plasma.
93
  The difference between TPM whole blood and plasma PK was more profound
at low doses (≤100 mg/day).  Walker and colleagues completed a correlation study to 
evaluate the feasibility of DBS collection in anticonvulsants.
243
  They did not report any
results for topiramate.
243
  The assays developed as a part of this project use similar
extraction methods to the previous reported assays, however, smaller sample volumes 
(100 μL) for plasma and whole blood assays and a smaller punch size (3 mm) for the 
DBS assay were developed to improve upon them. 
3.5 EXPERIMENTAL 
3.5.1 Chemicals 
TPM and TPM-d12 (internal standard) were purchased from Toronto Chemical Research 
(Ontario, Canada), the chemical structure shown in Figure 4.  Methanol and ammonium 
acetate were of HPLC grade and obtained from Fisher Scientific (MA, USA).  Mobile 
phase was a 20 mM ammonium acetate buffer made by dissolving 1.54 gm of ammonium 
acetate in 1 L of HPLC grade water.  The 1 L buffer was combined with 1 L of methanol.  
The buffer was filtered with 0.45 micron Nylon filters and degassed prior to use.  Perkin 
Elmer 226 Sample Collection Device cards were used for DBS analysis.  Perkin Elmer 
cards were chosen over other DBS cards because of the cost.  
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Figure 4: Chemical Structures of TPM and TPM-d12 
3.5.2 Equipment 
Instrument Conditions 
HPLC analysis was carried out on an Agilent 1100 LC MSD Model G1946 Mass 
Spectrometer.  Data were generated using Agilent ChemStation software.  The separation 
was performed using a Zorbex Eclipse XDB C18 column. The mobile phase consisted of 
ammonium acetate buffer and methanol (50:50, v/v).  The column temperature was 
maintained at 25°C.  The mass spectrometer ionization mode was electrospray with 
capillary voltage of 4000v and gas temperature of 300°C.  Total analysis run time was 10 
minutes. 
Assays 
An analytical method was developed based on previous literature and laboratory 
experience and validated according the Federal Food and Drug Administration guidance 
for whole blood, plasma, and DBS.
92
Topiramate Topiramate-d12 
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Preparation of Standard Solutions 
TPM-d12 was used as an internal standard (IS), a stock solution of the IS was prepared 
by dissolving 2.5 mg in 25 ml of methanol to produce a 20 mcg/ml working solution.  
Stock solutions of TPM were prepared at a concentration of 1 mg/ml in methanol.  The 
stock solutions were further diluted with methanol for the TPM working standard 
solution.  All the solutions were stored at -20 °C.  
 
Calibration standards were freshly prepared on a daily basis by spiking drug-free human 
whole blood or plasma with appropriate TPM working solutions, in order to produce 
seven TPM concentrations (0.6-30 mcg/ml).   
 
Preparation of Quality Control Samples 
A quality control (QC) stock solution of TPM was prepared at a concentration of 1 mg/ml 
in methanol by weighing 10 mg into a 10 ml volumetric flask and diluting with methanol.  
The stock solution was then stored in 2 dram vials at -20°C.  The QC stock solution was 
used to prepare QC samples at three TPM concentration levels: low, medium, and high.  
 
Whole blood QC pools (25 ml) were made by fortifying blank whole blood with 100, 
300, and 625 μL of QC solution volume to yield final concentrations of 4, 12, and 25 
mcg/ml.  Similarly, QC plasma pools (25 ml) were made by fortifying blank plasma with 
125, 375, and 625 μL of QC solution volume to yield final concentrations of 5, 15, and 
25 mcg/ml.  These QC samples were stored in polypropylene tubes at -20°C.  QC 
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samples for DBS were made by fortifying blank whole blood (5 ml) with 22.5, 75, and 
135 μL of QC solution volume to yield final concentrations of 4.5, 15, and 27 mcg/ml.  
Aliquots (30 μL) of QC samples were spotted onto Perkin Elmer 226 DBS cards and 
allowed to dry at room temperature for at least 3 hours.  The dried cards were stored in 
barrier foil ziplock bags (Ted Pella, Redding, CA) at -20°C.  QCs were analyzed during 
assay validation and with daily standard curves during sample analysis.  
Sample Preparation 
Ten microliters of each of the working calibration standards were added to 100 μL human 
whole blood or plasma aliquots to yield final concentrations of the calibration standards 
in the concentration range of 0.6-30 mcg/mL.  Ten microliters of IS were added to each 
tube and vortexed.  Two milliliters of methanol were added to each tube and vortexed for 
30 seconds.  The sample was then centrifuged for 10 minutes at 1500 rpm at 4°C.  The 
organic layer was transferred into a clean test tube.  The solution was evaporated under a 
stream of nitrogen at 37°C for about 40 minutes using Zymark TurboVap
®
 nitrogen
evaporator workstation.  The eluate was reconstituted with 200 μL of mobile phase.  The 
extract was transferred into an auto sampler vial and 10 μL was injected into the HPLC 
column. 
Similarly, ten microliters of each of the working calibration standards were added to 50 
μL human whole blood to yield final concentrations of the calibration standards in the 
concentration range of 0.6-30 mcg/mL.  Thirty microliters of the prepared spiked blood 
standards were spotted onto individual Perkin Elmer 226 cards (Perkin Elmer, Greenville, 
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SC), dried at room temperature for at least 3 hours and stored within a moisture-proof 
ziplock bag at -20°C until required for analyses.  For each DBS, a 3 mm diameter disk 
(Disposable Biopsy Punch with Plunger, Miltex, PA, USA) was punched manually and 
placed in an Eppendorf disposable tube.  Ten microliters of IS and 500 μL of methanol 
were added to the disc and the tube was vortex/mixed for 5 minutes.  The sample was 
then centrifuged for 5 minutes at 1000 rpm at 4°C.  The organic layer was transferred into 
a clean test tube.  The solution was evaporated under a stream of nitrogen at 37°C for 
about 20 minutes using Zymark TurboVap
®
 nitrogen evaporator workstation.  The eluate 
was reconstituted with 200 μL of mobile phase.  The extract was transferred into an auto 
sampler vial and 10 μL was injected into the HPLC column.   
 
Red Blood Cell-to-Plasma Partitioning Coefficient  
The RBC-to-plasma partitioning coefficient (KRBC:Plasma) characterizes the distribution of 
a compound between RBCs and plasma.  The RBC-to-plasma partitioning was 
established ex vivo using fresh human whole blood with a hematocrit value of 0.36, 
determined using URIT-12 Hemoglobin Meter (URIT Medical Electronic Co, China).  
The RBC-to-plasma partitioning coefficient was determined by two methods that have 
been reported in the literature.
244,245
   
 
In the method developed by Yu et al., an aliquot of 1 ml of human whole blood was 
pipetted into an Eppendorf polypropylene tube.  Twenty, 80, and 100 μL of TPM spiking 
solution was added so that the final concentrations were 4, 16, and 20 mcg/ml.  In 
parallel, fresh human plasma, prepared from the same batch of fresh whole blood, was 
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spiked with 20, 80, and 100 μL of TPM to obtain final concentrations of 4, 16, and 20 
mcg/ml.  The whole blood and plasma sample tubes were gently mixed.  The samples 
were then incubated at 37°C for 1 hour.  
For method comparison, TPM was also assayed using the traditional reported method.
245
TPM was added to whole blood to give a final concentration of 5, 10, and 20 mcg/ml.  
The samples were then incubated at 37°C for 1 hour.  The collected plasma or whole 
blood samples were extracted using a liquid-liquid extraction (described above).  The 
samples were run with seven calibration standards between 0.5-30 mcg/ml.  
3.6 RESULTS 
3.6.1 Assay Validation 
Validation of the developed methods was performed to evaluate the following 
parameters: selectivity, linearity, accuracy and precision, recovery, and stability.  
Validation followed the guidelines of the Federal Food and Drug Administration.
216
Selectivity 
Selectivity was determined by analyzing the blank samples from six independent sources 
for each matrix (whole blood, plasma, and DBS).  This ensured that the methods can 
differentiate and quantify the presence of other components in the sample and be 
selective for TPM.  TPM was found to be well resolved (Figure 5). 
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Figure 5: Chromatograph of Topiramate and Internal Standard.  Representative 
LC-MS chromatograms for topiramate (upper trace) and the internal standard 
(lower trace) in the human blood spot samples. 
 
 
Linearity 
A calibration curve is a general method for determining the concentration of a substance 
in an unknown sample by comparing the unknown to a set of standard samples of known 
concentrations.  Five calibration curves were prepared to determine the linearity and 
variability of the developed assay over a seven concentration range (0.5-30 mcg/ml) 
(Table 14) of TPM spiked in whole blood, plasma, and DBS samples.  Each run also 
consisted of a blank and a zero sample (blank matrix with IS added).  Calibration plots 
were constructed for peak area ratio (analyte response/IS response) versus the nominal 
analyte concentration in order to assess the relationship between the two parameters.  A 
weighted linear regression analysis was performed to determine the slope, intercept, and 
correlation coefficient of the calibration lines.      
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Table 15:  Final TPM concentrations of calibration standards and quality control 
samples prepared (mcg/ml) 
Several calibration curves were explored using GraphPad Prism
TM
.  These included the
1/X and 1/X
2
 weighted linear regression models.  Determination of the best fit was based
on accuracy and precision.  Evaluation of the best fit for each assay indicated that the 
1/X
2
 was optimal for whole blood while the 1/X was optimal for plasma and DBS.  The
calibration curves were found to be linear over the tested concentration range.  The 
correlation coefficient (r
2
) was 0.984 or better for all assays.  The mean correlation
coefficient, slope, and intercept values from the five calibration curves for each assay are 
presented in Table 16.  The average curve of the five calibration curves are shown in 
Figures 6-8.  The %CV at each concentration level for whole blood was <4.8%, with 
accuracy ranging from 91.5-95.9%.  The %CV at each concentration level for plasma was 
<4.5%, with accuracy 94.4-98.9%.  The %CV at each concentration level for DBS was < 
6.5% with accuracy 101.5-106.7%.     
Table 16: Mean slope, intercept and correlation coefficient according to the 
calibration curves plotted (n=5) 
Assay Mean Slope + SD Mean Intercept + SD Mean Correlation 
Coefficient (r
2
) + SD
Whole Blood 0.624 + 0.042 -0.099 + 0.028 0.991 + 0.005 
Plasma 0.630 + 0.015 -0.119 + 0.031 0.993 + 0.003 
DBS 0.136 + 0.011 -0.033 + 0.012 0.991 + 0.002 
Assay C1 C2 C3 C4 C5 C6 C7 LQC MQC HQC 
Whole Blood 0.6 1.2 3 6 12 24 30 4 12 25 
Plasma 0.6 1.2 3 6 12 24 30 5 15 25 
DBS 0.6 1.2 3 6 12 24 30 4.5 15 27 
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Figure 6:  The area response ratio against concentration of TPM in whole blood 
samples.  The response of the instrument with regard to the concentrations of TPM 
in whole blood samples over 5 days.  
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Figure 7:  The area response ratio against concentration of TPM in plasma samples.   
The response of the instrument with regard to the concentrations of TPM in plasma 
samples over 5 days.  
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Figure 8:  The area response ratio against concentration of TPM in DBS samples.   
The response of the instrument with regard to the concentrations of TPM in DBS 
samples over 5 days.  
 
Accuracy and Precision 
Within and between day accuracy and precision data were determined for quality control 
samples for each assay during the 5-day validation (Table 17).  In addition to accuracy 
and precision, there was no statistical difference between days for each assay based on 
parametric (ANOVA) analysis (p-values > 0.53) (Tables 18-20).     
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  Table 17: Summary of inter-day accuracy and precision for each assay 
Assay Nominal Conc. 
(mcg/ml) 
Intra-day Inter-day 
 Accuracy (%) Precision 
(%CV) 
Accuracy 
(%) 
Precision 
(%CV) 
WB LQC      4 
MQC    12 
HQC     25 
88.5-93.1 
92.2-98.7 
88.9-95.7 
1.1-5.1 
1.8-9.4 
1.7-8.4 
91.5 
95.9 
92.8 
3.4 
4.8 
3.9 
Plasma LQC      5 
MQC    15 
HQC     25 
92.4-100.5 
91.5-99.1 
92.4-99.1 
0.6-5.6 
0.9-4.5 
1.8-6.1 
95.4 
94.4 
98.9 
4.5 
4.4 
4.5 
DBS LQC     4.5 
MQC    15 
HQC     27 
89.7-106 
97.2-113.97 
99.6-114.57 
1.8-5 
0.5-8.3 
0.8-9.3 
101.5 
106.7 
106.5 
5.8 
6.3 
6.5 
 
Table 18: Mean concentration per day of quality control samples for plasma assay 
 Day 1 Day 2 Day 3 Day 4 Day 5 
LQC 5.0 (0.03) 4.7 (0.27) 4.8 (0.09) 4.7 (0.15) 4.6 (0.20) 
MQC 14.9 (0.57) 13.9 (0.44) 14.1 (1.32) 13.8 (0.30) 13.7 (0.12) 
HQC 24.8 (0.86) 23.1 (0.41) 23.7 (1.45) 23.7 (1.36) 23.4 (0.47) 
 
Table 19: Mean concentration per day of quality control samples for whole blood 
assay 
 Day 1 Day 2 Day 3 Day 4 Day 5 
LQC 3.7 (0.07) 3.6 (0.04) 3.7 (0.19) 3.7 (0.11) 3.5 (0.06) 
MQC 11.9 (0.51) 11.4 (0.20) 11.6 (0.51) 11.3 (1.07) 11.1 (0.47) 
HQC 23.9 (0.61) 23.1 (0.40) 23.3 (0.49) 22.9 (1.93) 22.2 (0.56) 
 
Table 20: Mean concentration per day of quality control samples for DBS assay 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
LQC 4.6 (0.09) 4.4 (0.08) 4.7 
(0.19) 
4.7(0.23) 4.8 
(0.19) 
4.6 
(0.22) 
4.5 (0.19) 
MQC 15.1(0.61) 16 (0.37) 16.8 
(0.47) 
17.1 
(0.09) 
15.9 
(1.33) 
16.6 
(0.48) 
16.5 
(0.46) 
HQC 26.89 
(1.86) 
29.14 
(0.56) 
30.94 
(0.26) 
28.76 
(0.74) 
28.14 
(2.60) 
30.49 
(0.62) 
28.53 
(0.95) 
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Percent Recovery  
Percent recovery of each assay was determined by comparing the detector response 
obtained from a known amount of analyte added to, and extracted from, the biological 
matrix with the detector response obtained from the true concentration of the unextracted 
standard representing 100% recovery.  The calculated recoveries for the whole blood, 
plasma, and DBS were 80%, 98%, and 96%, respectively.   
 
Limit of Detection (LOD) and Limit of Quantification (LLOQ) 
The LOD and LLOQ were calculated using the following formula
246
:  
𝐿𝑂𝐷 =  
3.3𝜎
𝑆
     𝐿𝐿𝑂𝑄 =  
10𝜎
𝑆
 
where σ is the standard deviation of the response, S is the slope of the calibration curve.  
The results for the LOD and LLOQ for each assay are shown in Table 21. 
Table 21: LOD and LLOQ for each assay 
Assay LOD (mcg/ml) LLOQ (mcg/ml) 
WB 0.15 0.45 
P 0.16 0.49 
DBS 0.39 1.18 
 
Red Blood Cell-to-Plasma Partitioning Coefficient  
Two methods were used to measure RBC partitioning of topiramate.
244,245
  Both methods 
yielded comparable results (Figure 9 and 10).  The mean at each concentration level are 
shown in Table 21 and 22.  RBC partitioning of a compound may be concentration-
dependent if the partitioning involves not only passive diffusion, but also protein binding, 
RBC components binding or active transporters.
244
  As indicated in Figure 9 and 10, the 
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partitioning of TPM was concentration-dependent in the concentration range of 1 – 20 
mcg/ml.   
 
Table 22: Mean values of concentration based on new assay method 
Nominal 
Concentration 
(mcg/ml) 
Reference Plasma 
Concentration 
(mcg/ml) (Mean + SD) 
Equilibrated Plasma 
Concentration 
(mcg/ml) (Mean + 
SD) 
Calculated KRBC/P 
(Mean + SD) 
0.8 (N=3) 0.78 + 0.03 0.22 + 0.01 22.89 + 3.40 
4 (N=8) 4.49 + 0.45 1.33 + 0.69 8.45 + 4.04 
16 (N=8) 17.36 + 6.43 13.48 + 6.12 3.96 + 0.33 
20 (N=9) 22.61 + 6.49 16.46 + 5.99 1.94 + 0.07 
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Figure 9: Effect of topiramate concentration on RBC partitioning using reference 
plasma and equilibrated plasma.  Effect of compound concentration on RBC 
partitioning (incubation time: 60 minutes) (N=28). 
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Table 23: Mean values of concentrations based on traditional assay method 
Nominal 
Concentration 
(mcg/ml) 
Spiked Conc. 
Whole  
Blood 
(mcg/ml) 
(Mean + SD) 
Analyzed 
Conc. 
Plasma 
(mcg/ml) 
(Mean + SD) 
Blood-
to-
Plasma 
Ratio 
Calculated 
Conc. 
RBC 
(mcg/ml) 
RBC-to-
Plasma 
Partitioning 
5 (N=4) 5.25 + 0.12 2.87 + 0.30 1.85 + 
0.18 
9.19 + 0.29 3.22 + 0.38 
10 (N=4) 9.89 + 0.35 7.22 + 0.12 1.38 + 
0.06 
14.27 + 
1.08 
1.99 + 0.12 
20 (N=3) 19.66 + 0.65 17.33 + 0.29 1.14 + 
0.05 
23.47 + 
2.04 
1.36 + 0.14 
 
0 5 1 0 1 5 2 0 2 5
0
1
2
3
4
N o m in a l C o n c e n tra tio n  (m c g /m l)
R
B
C
-t
o
-P
la
s
m
a
 P
a
r
ti
ti
o
n
in
g
 
Figure 10: Effect of topiramate concentration on RBC partitioning using whole 
blood and plasma.  Effect of compound concentration on RBC partitioning 
(incubation time: 60 minutes) (N=11). 
 
3.7 CONCLUSION 
The method developed for the quantification of TPM in whole blood, DBS, and plasma 
was successfully validated according to FDA guidelines.  Perkin Elmer cards were shown 
to be suitable for this application.  We demonstrated that the difference in extraction 
recovery between assays is small suggesting topiramate can be measured in a whole 
blood, plasma, and DBS.  Successful validation confirmed that these methods are suitable 
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for the determination of TPM in whole blood, plasma, and DBS samples in the following 
studies and will be used to determine TPM concentratin in canine and human samples.      
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CHAPTER 4: WHOLE BLOOD TPM PHARMACOKINETICS FOR 
INTRAVENOUS AND ORAL DOSING IN DOGS WITH NATURALLY-
OCCURRING EPILEPSY 
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4.1 INTRODUCTION 
An intravenous formulation could be beneficial for use in adults and animals; however, 
low drug solubility hindered its development.  Researchers at the Center for Orphan Drug 
Research (CODR) overcame this challenge by using a cyclodextrin excipient to increase 
solubility.  Based on this work, a novel IV TPM formulation, 10 mg/ml dissolved in 10% 
sulfobutyl cyclodextrin (Captisol®), was developed by the CODR at the University of 
Minnesota which has been licensed to CureX.  Cyclodextrins are complex molecules that 
have a hydrophilic exterior and a lipophilic interior cavity.  These molecules can improve 
drug solubility and stability by attracting poorly water soluble compounds into the cavity 
while the cyclodextrin-drug combination remains in solution.  Drug rapidly dissociates 
from the cyclodextrin once the solution is injected into the bloodstream.
247,248
  Captisol® 
(Cydex) is a polyanionic β-cyclodextrin derivative that has an improved safety profile 
over other the parent β-cyclodextrin by eliminating the potentially damaging effects.  It 
has been shown to be safe in humans and has received FDA approval for use in parental 
formulations of voriconazole (VFEND®), aripiprazole (Abilify®), and ziprasidone 
(GEODON®).   
 
Two studies have been completed in adult patients (n=20) and healthy volunteers (n=12) 
that established the PK and safety of the IV TPM.
91,92,249
  The first study reported the PK 
parameters and safety of IV TPM in patients with epilepsy or migraines.  The second was 
a two-way crossover study of oral and IV TPM in healthy volunteers designed to 
determine safety, estimate PK parameters, and determine oral bioavailability.  The results 
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of these two studies show the absolute bioavailability of oral TPM is approximately 
100%.   
 
Canine epilepsy closely resembles human epilepsy and is being utilized by our research 
group to study approved and investigational antiepileptic drugs.  An ongoing study of 
TPM in these dogs allowed further exploration of the nonlinear relationship between 
TPM plasma and whole blood concentrations. 
 
The objective of this study was to characterize the PK of IV and oral TPM in dogs and 
the relationship between plasma and whole blood concentrations.  This is the first animal 
study to determine whole blood TPM PK and the relationship between whole blood and 
plasma topiramate concentrations.       
 
4.2 STUDY AIMS 
The primary objectives of this study were to compare the PK of IV TPM in plasma and 
whole blood and describe the relationship between whole blood and plasma 
concentrations in dogs with naturally occurring epilepsy. 
 
Aim #1: Characterize the relationship between whole blood to plasma TPM 
concentrations in dogs. 
 
Aim #2: Characterize and compare the TPM pharmacokinetics measured in whole blood 
and plasma.  
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4.3 STUDY METHODS 
4.3.1 Animals and Study Design 
Animal experiments were conducted in accordance with the Animal Welfare Act for the 
care and use of laboratory animals.  The project was approved by the University of 
Minnesota Institutional Animal Care and Use Committee.  The experiment was carried 
out in four dogs with naturally occurring epilepsy.  Dogs were housed at the Veterinary 
Center at University of Minnesota in St. Paul, Minnesota.  Animals were fasted overnight 
prior to each dose and were 2 hours post-injection.  
 
Each dog was administered a single dose of 10 mg/kg stable-isotope (
13
[C]6) topiramate 
via a bolus injection (over 5 minutes) and 5 mg/kg non-labeled topiramate orally 1 hour 
post-injection.  The oral TPM was given 1 hour post-injection so it would not produce 
confounding factors when recording the response of the IV TPM on iEEG recordings 
(data not presented in this thesis).  A second dose of 20 mg/kg was administered to three 
additional dogs.  Whole blood samples (~2 ml) were collected via catheterized vein pre-
dose and at 0, 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 9, and 24 hours post-injection 
(Table 24).  A 250 μL sample of whole blood was aliquoted, the remaining blood was 
placed on ice, plasma separated, and immediately frozen (-20°C) until analysis.  Missed 
samples were recorded. 
 
Table 24: Blood Collection Times (in minutes) 
IV predose 0 5 15 30 45 60 90 120 150 180 240 360 480 540 
ORAL  0 30 60 90 120 180 300 420 480 
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4.3.2 Study Drug and Dose Rationale  
Stable-labeled IV TPM solution was provided by CODR and unlabeled TPM tablets (100 
mg, Johnson and Johnson) were purchased by the Veterinary Medical Pharmacy.  The 
pharmaceutical grade unlabeled TPM tablets were purchased from the Pharmacy at the 
Veterinary Medical Center.  The stable-labeled topiramate solution was prepared by the 
Pharmaceutical Service Division at the University of Iowa under good manufacturing 
procedures.  The solution is 10 mg/ml topiramate in 10% Captisol®.
249
  Using 
intravenous data from one dog in a study by Streeter et al, we estimated an apparent 
volume of distribution of 0.63 L/kg.
250
  Thus, in a healthy beagle dog, a 10 mg/kg 
intravenous dose of topiramate was estimated to produce an initial concentration (C0) of 
15.9 mcg/ml.   
 
4.3.3 Drug Assay 
Whole blood topiramate concentrations were quantified using the LC-MS method 
described in Chapter 3.    
 
4.3.4 TPM Binding to Carbonic Anhydrase 
TPM dissociation binding constant (KD) and maximum binding capacity (Bmax) values for 
its saturable binding to erythrocytes was obtained by applying equation 1 that contained 
either 1 or 2 binding sites to the data.   
 
 
𝐶𝐵 =  
𝐵𝑚𝑎𝑥 ∗ 𝐶𝑃
𝐶𝑃 +  𝐾𝐷
+  
𝐵𝑚𝑎𝑥2 ∗ 𝐶𝑝
𝐶𝑝 +  𝐾𝐷2
 
(1) 
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In equation 1, CB represents the bound concentration of TPM and Cp represents the total 
concentration in plasma.  Kinetic constants were obtained using a non-linear regression 
analysis to fit the data, assuming either 1 or 2 saturable binding sites (Phoenix software, 
Version 6.3; Pharsight Corporation, Mountain View, CA, USA).  The results of the one-
site model versus the two-site model were compared for statistical significance using an 
F-test.   
 
4.3.5 Pharmacokinetic Analysis Methods 
Non-compartmental analysis 
Concentration-time data from the intravenous and oral administrations were analyzed to 
obtain area under the curve (AUC), clearance, half-life, volume of distribution, and 
bioavailability using a non-compartmental PK approach with Phoenix software 
(WinNonLin, Version 6.3; Pharsight Corporation, Mountain View, CA, USA).  All data 
was weighed using uniform weighing.  To determine the absolute bioavailability, the 
areas under the concentration-time curve for both the oral and intravenous topiramate 
were calculated.  The AUC0-∞ was calculated using a log-linear trapezoidal method with 
the tail area calculated from Clast/k.  The terminal rate constant (k) was determined by 
linear regression of the terminal phase on log concentration versus time plots.  Terminal 
half-life (T1/2) was calculated as 0.693/k.   
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The maximum concentration (Cmax) was the highest observed whole blood oral TPM 
concentration.  Clearance was estimated by dose divided by AUC0-∞.  Volume of 
distribution was estimated by dose divided by k*AUC0-∞.   
 
Bioavailability (F) for each dog and mean bioavailability was determined by calculating 
the ratio of the dose normalized oral area under the concentration-time curves (AUC0-∞) 
to the dose normalized intravenous area under the concentration-time curves (AUC0-∞) 
(Equation 2). 
 
 
𝐹 =  
𝐷𝑜𝑠𝑒𝐼𝑉 𝑥 𝐴𝑈𝐶𝑂𝑟𝑎𝑙
𝐷𝑜𝑠𝑒𝑂𝑟𝑎𝑙 𝑥 𝐴𝑈𝐶𝐼𝑉
 
(2) 
 
Compartmental analysis 
Concentration-time data were analyzed using compartmental methods (WinNonLin, 
Version 6.3; Pharsight Corporation, Mountain View, CA, USA).  One- and two-
compartmental models were evaluated.  Data were analyzed using different weighting 
schemes (1/y, 1/y
2, 1/ŷ, 1/ŷ2).  Models were compared using visual inspection, goodness 
of fit plots, weighted residual plots, precision of model parameters, weighted residual 
sum of squares, and Akaike’s information criterion. 
 
4.4 RESULTS 
A total of 7 dogs were used in this experiment.  Four dogs received an intravenous bolus 
TPM dose of 10 mg/kg and an oral topiramate dose of 5 mg/kg 60 minutes after the IV 
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dose.  An additional three dogs received an intravenous bolus TPM dose of 20 mg/kg.  
The dogs weighed between 15-34 kilograms at the time of dosing.  Three dogs were on 
comedications (PB, PB and LEV, or PB and LEV, and zonisamide (ZNS)).  There were a 
total of 51 missing blood samples out of 98 total samples for all dogs due to limited 
amount of sample or the blood sample was not separated prior to centrifuging.   
 
The individual concentration-time profiles of labeled and unlabeled TPM are shown in 
Figure 11-13, respectively.  The graphs show two distinct groups, dogs which were on 
enzyme-inducing medication and dogs which were not on any medications.  
Concentrations were substantially lower in the inducer group.  Concentrations fall below 
10 mcg/ml at 30 minutes for inducers whereas concentrations didn’t fall below 10 
mcg/ml until 480 minutes for non-inducers.  Figure 13 shows that the Tmax ranged from 
1-2 hours in all dogs and Cmax ranged from 2-8 mcg/ml.    
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Figure 11:  Individual whole blood concentration-time profile for 10 mg/kg labeled 
IV topiramate.  The symbols represent each dog.  Circles: dog 1, squares: dog 2, 
triangles: dog 3, and inverted triangles: dog 4.   
 
 
 
 
108 
 
0 2 0 0 4 0 0 6 0 0
0
1 0
2 0
3 0
4 0
5 0
T im e  (m in )W
h
o
le
 B
lo
o
d
 C
o
n
c
e
n
tr
a
ti
o
n
 (
m
c
g
/m
l)
0 2 0 4 0 6 0
0
1 0
2 0
3 0
4 0
5 0
T im e  (m in )W
h
o
le
 B
lo
o
d
 C
o
n
c
e
n
tr
a
ti
o
n
 (
m
c
g
/m
l)
 
Figure 12: Individual whole blood concentration time profile for 20 mg/kg labeled 
IV TPM.  The symbols represent each dog.  Triangles: dog 3, inverted triangles: dog 
4, and diamond: dog 5. 
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Figure 13: Individual whole blood concentration-time profile for unlabeled oral 
topiramate.  The symbols represent each dog.  Circles: dog 1, squares: dog 2, 
triangles: dog 3, and inverted triangles: dog 4. 
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4.4.1 Non-compartmental analysis 
Table 25 summarizes the individual PK parameters for all dogs.  The clearance of 
topiramate was 0.3 and 0.6 L/hr/kg in dogs on inducing comedication and 0.04 and 0.07 
L/hr/kg in dogs not on inducing comedication.  The dogs with the highest clearance were 
on PB, an inducing AED.  The volume of distribution was 0.06 to 0.68 L/kg in inducers 
and 0.23 and 0.4 in non-inducers.  In dogs on PB, the half-life was 0.9 to 1.7 hours.  In 
dogs not on additional medications, the half-life was 4.2 and 4.6 hours.  The half-life 
increased to 6.4 and 7.0 hours for non-inducers on the higher dose.  The mean absolute 
bioavailability for orally administered topiramate was 87% + 40% with a range of 57% to 
144%.  The maximum concentration of the stable-labeled topiramate after 10 mg/kg and 
20 mg/kg given intravenously was 38.4 mcg/ml and 37.7 mcg/ml and was not affected by 
whether they were on enzyme-inducing medication.   
 
Table 25: Individual pharmacokinetic parameters 
ID Dose 
(mg/
kg) 
CL 
(L/hr/
kg) 
Vd 
(L/k
g) 
T1/2 
(hr) 
Cmax,oral 
(mcg/ml) 
AUC0-∞,iv 
(mcg*hr/ml) 
AUC0-
∞,oral 
(mcg*hr/
ml) 
F 
(%) 
Inducing 
Comed 
1 10 0.05 0.06 0.9 4.5 203.4 12.3 62 Yes 
2 10 0.30 0.42 1.0 2.7 33.11 11.5 144 Yes 
3 10 0.04 0.23 4.6 7.7 236.1 67.1 57 No 
4 10 0.06 0.37 4.2 9.8 145.1 61.8 85 No 
3 20 0.06 0.56 7.0 NC 359.9 NC NC No 
4 20 0.07 0.63 6.4 NC 291.0 NC NC No 
5 20 0.30 0.68 1.7 NC 67.3 NC NC Yes 
NC: not calculated 
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4.4.2 Compartmental analysis 
One and two-compartment intravenous infusion models were evaluated using the whole 
blood TPM concentrations.  A one-compartment model best fit the data.  Goodness of fit 
plots, including weighted residuals versus time and observed versus predicted values are 
shown in Figure 14 through Figure 15.  While the residual plot suggested a two-
compartment model may be better, the parameter estimates were unstable with poor 
precision (high CVs).  This is likely because of the small sample size and lack of samples 
at the early time points.  A weighting scheme of 1/ŷ was used for the intravenous 1-
compartment model and 1/ŷ2 for oral 1-compartment.   
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Figure 14: Goodness of fit for one-compartment model after intravenous dose in all 
dogs. (a) Identity plots of observed vs. individual predicted TPM concentration.  (b) 
Scatter plot of weighted residuals (WRES) vs. time.  Line of identity (solid); 
regression line (dashed) 
  
(a) (b) 
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Figure 15: Goodness of fit for one compartment model after oral dose.  (a) Identity 
plots of observed vs. individual predicted TPM concentration.  (b) Scatter plot of 
weighted residuals (WRES) vs. time.  Line of identity (solid); regression line 
(dashed) 
 
The individual PK parameters for the 1-compartment IV and oral TPM model are shown 
in Table 26 and Table 27.  The individual PK parameters from the one-compartment 
model compared closely to the results from the non-compartmental analysis.  The 
clearance for non-inducers was 0.04 – 0.07 L/hr/kg with the non-compartmental methods 
compared to 0.03 – 0.1 L/hr/kg with the 1-compartment model.  The half-life was 0.9 – 1 
and 1 - 1.4 hours with the non-compartmental and 1-compartment models for inducers, 
respectively.  The half-life ranged from 4.2 – 4.6 and 5.1 – 8.3 hours with the non-
compartmental and 1-compartment models for non-inducers, respectively.    
 
 
 
 
 
(a) (b) 
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Table 26: Individual 1-compartment pharmacokinetic parameters after intravenous 
topiramate 
 ID Dose 
(mg/kg) 
Vd 
(L/kg) 
T1/2 
(hr) 
CL 
(L/hr/kg) 
K10 
(1/hr) 
Inducers       
 1 10 0.2 1.0 0.2 0.9 
 2 10 0.7 1.0 0.5 0.7 
 5 20 0.6 1.4 0.3 0.5 
Non-inducers       
 3 10 0.4 8.1 0.03 0.09 
 4 10 0.4 5.3 0.1 0.13 
 3 20 0.6 6.9 0.1 0.10 
 4 20 0.6 6.3 0.1 0.11 
 
Table 27: Individual 1-compartment pharmacokinetic parameters after oral 
topiramate 
 ID Vd 
(L/kg) 
T1/2 
(hr) 
CL 
(L/hr/kg) 
K10 
(1/hr) 
Cmax 
(mcg/ml) 
AUC 
(mcg*hr/ml) 
Inducers        
 1 1.0 1.9 0.4 0.4 3.2 13.3 
 2 1.0 1.6 0.4 0.4 1.8 11.2 
Non-inducers        
 3 0.6 6.3 0.07 0.1 7.1 72.1 
 4 0.4 3.1 0.08 0.2 8.9 61.2 
 
4.4.3 Comparison of Plasma and Whole Blood Pharmacokinetics 
Figure 16-19 show individual concentration-time data for whole blood and plasma 
concentrations after intravenous dosing and oral dosing separated by inducing and non-
inducing medications.  Concentrations for the non-inducing dogs have a larger difference 
between whole blood and plasma TPM concentrations.  
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Figure 16: Concentration-time profile after intravenous dosing for inducers.  The 
symbols represent dog 1 (circles), dog 2 (triangles), and dog 5 (diamonds).  Open 
symbol represents plasma concentrations and filled symbol represent whole blood 
concentrations. 
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Figure 17: Concentration-time profile after intravenous dosing for non-inducers.   
The symbols represent dog 3 at 10 mg/kg dose (circles), dog 3 at 20 mg/kg dose 
(inverted triangles), dog 4 at 10 mg/kg dose (squares) and dog 4 at 20 mg/kg dose 
(diamonds).  Open symbol represents plasma concentrations and filled symbol 
represent whole blood concentrations.  
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Figure 18: Concentration-time profile after oral dosing for inducers.  The symbols 
represent dog 1 (circles) and dog 2 (triangles).  Open symbol represents plasma 
concentrations and filled symbol represent whole blood concentrations. 
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Figure 19: Concentration-time profile after oral dosing for non-inducers.  The 
symbols represent dog 3 (circles) and dog 4 (squares).  Open symbol represents 
plasma concentrations and filled symbol represent whole blood concentrations. 
 
Individual PK parameters for whole blood and plasma are shown in Table 28.  While 
maximum concentrations in whole blood and plasma were similar, AUCs were greater in 
whole blood resulting in lower clearance.  Non-compartmental analysis showed the 
clearance of TPM ranged from 0.04 to 0.30 L/hr/kg and 0.11 to 0.88 L/hr/kg for whole 
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blood and plasma, respectively.  The volume of distribution varied from 0.06 to 0.68 L/kg 
and 0.5 to 0.7 L/kg for whole blood and plasma, respectively.  The half-life ranged from 
0.9 to 4.6 hours and 0.5 to 3.7 hours for whole blood and plasma.  Half-life and clearance 
were affected by inducing comedication use to the same degree for both whole blood and 
plasma.  
 
Table 28: Individual intravenous non-compartmental pharmacokinetic parameters 
for whole blood and plasma 
 ID Vd (L/kg) T1/2 
(hr) 
CL (L/hr/kg) AUC0-∞ 
(mcg*hr/ml) 
Whole Blood      
 1 0.06 0.9 0.05 203.4 
 2 0.42 1.0 0.30 33.1 
 3 0.23 4.6 0.04 236.1 
 4 0.37 4.2 0.06 145.1 
 5 0.68 1.7 0.30 67.3 
Plasma      
 1 0.59 0.5 0.88 11.4 
 2 0.50 0.7 0.46 21.7 
 3 0.66 3.7 0.12 81.7 
 4 0.66 3.5 0.11 94.5 
 5 0.70 0.9 0.15 38.1 
 
4.4.4 TPM Binding to Carbonic Anhydrase  
Whole blood and plasma concentrations were different at lower concentrations.  
Additionally, the whole blood-to-plasma ratio changed with plasma concentrations being 
higher at lower plasma concentrations indicating that TPM is distributing into RBCs.  
The distribution into RBCs is likely due to its binding to carbonic anhydrase isoforms 
that are present in high concentrations in the erythrocytes.
251
  Figure 20 shows the whole 
blood/plasma concentration ratio for TPM as a function of the plasma concentration 
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excluding the dog taking ZNS.  The figure suggests there is greater binding at lower 
concentrations that becomes saturated as plasma concentration increases.   
 
Binding analysis revealed that binding comprised a saturable component (Figure 20).  
When a single binding site model was assumed, the optimal fit yielded a KD of 1.2 
mcg/ml (95% confidence interval, CI = 0.3 – 2.6) and a Bmax of 2.9 mcg/ml (95% 
confidence interval, CI = 1.9-3.8).  The two saturable binding sites model was unable to 
fit the data and was over-parameterized given the small sample size.           
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Figure 20: Plot of the whole blood/plasma concentration ratio for TPM as a function 
of plasma concentration.  The curvilinear line was formed by a curve-fit analysis of 
the data assuming one saturable binding site.  
 
4.5 DISCUSSION 
This pilot study examined the whole blood PK of IV and oral TPM in dogs and compared 
plasma and whole blood TPM concentrations.  Similar to humans, there was a nonlinear 
relationship between plasma and whole blood concentrations in which whole blood TPM 
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concentrations are 1.3-3.9 times greater than plasma concentrations.  This relationship is 
important when predicting plasma concentration from whole blood and appears to apply 
to both dogs and humans.  Caution should be exercised in interpreting whole blood TPM 
concentrations as one may overestimate plasma concentrations by as much as 4 fold.   
 
Erythrocytes of dogs also contain CA-I and CA-II where CA-II has higher enzymatic 
activity which is similar to humans.
251
  There was one dog that had lower and more 
constant plasma to whole blood ratios.  Interestingly, this dog was taking ZNS as a 
concomitant medication.  ZNS is structurally similar to topiramate and has also been 
suggested to bind to the two isoforms of carbonic anhydrase in red blood cells.
252
   This 
may suggest competitive binding between TPM and ZNS.  This dog was excluded from 
the analysis of TPM binding to carbonic anhydrase.  The one saturation binding site 
model had a higher KD  and lower Bmax than values reported previously in humans.
93
  
Given the small number of samples collected, the parameters for the two saturable 
binding site model were not able to be estimated.  Previous reports have described a two 
saturable binding site model which would be expected given the two isoforms of carbonic 
anhydrase located in the red blood cells.   
 
There was a difference in PK parameter estimates with those derived from whole blood 
generally showing reduced clearances and volumes resulting in longer elimination half-
lives.  This study found the mean oral bioavailability was 78% which is greater than the 
range of 27 to 59% that has been reported for beagle dogs.
250
  However, half-life was 
similar to a previously reported study, 3.4 hours compared to 4.4 hours for non-
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inducers.
250
  When using TPM in dogs, consideration should be taken if the animals are 
on known enzyme inducers as they may need higher doses to attain the target 
concentrations.   
 
While the established PK model did provide useful information it is limited by both the 
small number of dogs and the limited sample volume in whole blood.  The observation of 
a difference between whole blood and plasma is supported by other work in humans.
93,235
  
The small sample size resulted in the two compartment model being unstable.  Non-
compartmental and the one-compartmental analysis resulted in elimination half-life, 
clearance, and volume of distribution values that agree well with previously published 
literature.
250
   
 
Assuming the rapid distribution of TPM from plasma to other body compartments 
includes the central nervous system; IV TPM may be useful in treating canine seizure 
emergencies and may have potential use in human seizure emergencies.   
 
This work demonstrates that using a small number of dogs can be informative in 
establishing the PK of an AED therapy and characterizing the binding properties of 
topiramate to carbonic anhydrase in the red blood cells.  Further study is needed on the 
use of IV TPM for seizure emergencies. 
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CHAPTER 5: COMPARISON OF TOPIRAMATE CONCENTRATIONS IN 
WHOLE BLOOD AND PLASMA IN ADULTS AND CHILDREN 
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5.1 INTRODUCTION 
The goal of this research project is to characterize the relationship of whole blood, DBS, 
and plasma TPM concentrations in adults and children.   
 
DBS technology has a number of advantages over conventional sample collection.  These 
include practical, clinical, and cost considerations.  Use of DBS technology allows for 
less invasive sampling (finger or heel prick rather than a venipuncture) and as much as a 
90% reduction blood volume needed to perform the assay.  Further, use of DBS can 
simplify sample collection and make shipping of samples easier. However, as previously 
discussed (Chapter 3), one problem with using DBS to measure TPM levels is that TPM 
exhibits saturable binding to carbonic anhydrase in red blood cells.
93
  This creates a 
nonlinear relationship between whole blood and plasma concentrations and results in 
higher whole blood concentration versus plasma concentration, particularly at TPM 
concentrations near the lower limit of its reference range (2-20 mg/L).
218,219
  Thus, TDM 
of TPM using whole blood as a matrix may mislead the clinician, as a plasma or serum is 
the normal matrix where TPM is measured.  Further, PK parameters determined using 
TPM concentrations derived from whole blood may differ from those based on plasma-
based assay, resulting in confusion about a drug’s disposition.  
 
Few studies have been reported using DBS for TPM.  One study used DBS in children 
between 0.9-16 years to determine adherence of antiepileptic medications.
217
  They 
concluded that DBS was a useful approach to adherence assessment when combined with 
other measures including self-reporting.  Information about TPM concentrations in 
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children measured with DBS is limited.  Two studies have evaluated TPM concentrations 
in neonates using DBS.
109,110
  These studies converted the DBS concentrations into 
plasma concentrations using a possibly flawed assumption that could result in incorrect 
estimation of plasma TPM concentrations.  There are no published reports that have 
characterized the relationship of TPM concentrations measured in blood and plasma of 
children.     
 
5.2 STUDY AIM 
The primary objective of this study is to compare TPM concentrations measured in whole 
blood, DBS, and plasma in samples obtained from adults and children taking TPM for 
any indication.   
 
The Specific Aim of this project is to: 
Aim #1: Characterize the relationship between whole blood or DBS TPM concentrations 
to plasma TPM concentrations in human samples 
 
5.3 METHODS    
5.3.1 Subjects and Study Procedures 
Thirty (30) adult patients, 18 years of age and older and eight (8) pediatric patients, ages 
5 years to 12 years, were enrolled in the study.  Patients were recruited from the MINCEP 
Clinic of the University of Minnesota Physicians, Gillette Children’s Specialty 
Healthcare, and the Minnesota Epilepsy Group Clinic.  The study was approved by the 
IRB at the University of Minnesota.   
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Prospective subjects were identified from the participating clinic database, eligibility 
reviewed by the principal investigator, and potential subjects were presented to the 
attending physician.  The attending physician briefly reviewed the study with the patient 
during the routine clinic visit.  If the subject was interested, the principal investigator 
further discussed the study with patients at their clinic visit, answered any questions and 
invited the patient to participate in the study.  Informed consent was then presented to 
potential subjects after their clinic visit.  Subjects unwilling to have blood drawn or a 
finger-prick were excluded.   
  
Two one-milliliter blood samples were collected.  One blood sample was used to assay 
TPM in whole blood and the second was processed for plasma for measurement of TPM 
concentations.  Patients also underwent a finger prick to collect a DBS.   
 
Drug Assay 
The analytical method was designed to measure TPM in plasma, whole blood, and DBS 
using LC-MS.  These methods are described in Chapter 3.   
 
5.4 DATA ANALYSIS    
5.4.1 TPM Binding to Carbonic Anhydrase  
TPM dissociation binding constant (KD) and maximum binding capacity (Bmax) values for 
its saturable binding to erythrocytes was obtained by applying equation 3 that contained 
either 1 or 2 binding sites to the data.   
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𝐶𝐵 =  
𝐵𝑚𝑎𝑥 ∗ 𝐶𝑃
𝐶𝑃 +  𝐾𝐷
+  
𝐵𝑚𝑎𝑥2 ∗ 𝐶𝑝
𝐶𝑝 +  𝐾𝐷2
 
(3) 
 
where CB represents the bound concentration of TPM and Cp represents the total 
concentration in plasma.  Kinetic constants were obtained using a non-linear regression 
analysis to fit the data, assuming either 1 or 2 saturable binding sites (Phoenix software, 
Version 6.3; Pharsight Corporation, Mountain View, CA, USA).  The results of the one-
site model versus the two-site model were compared for statistical significance (p-value < 
0.05) using an F-test.   
  
5.4.2 Estimation of Plasma Concentrations  
Whole blood is composed of serum, red blood cells, white blood cells, and platelets; 
where the fractional volume of white blood cells and platelets is negligible.  The plasma-
to-whole blood concentration ratio depends on plasma protein binding, partitioning into 
blood cells, and the volume occupied by blood cells.  The following equation can 
describe this relationship, where Cb is the TPM concentration in whole blood, Cp is the 
TPM concentration in plasma, Vp is the plasma volume, CRBC is the TPM concentration 
in red blood cells, VRBC is the volume occupied by the red blood cells, and Vb is the 
volume of whole blood. 
 
 𝐶𝑏 ∗ 𝑉𝑏 =  𝐶𝑝 ∗ 𝑉𝑝 +  𝐶𝑅𝐵𝐶 ∗ 𝑉𝑅𝐵𝐶 (4) 
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The concentration of analyte in whole blood can then be calculated from the following 
equation.   
 
 
𝐶𝑏 =  
𝐶𝑝 ∗ 𝑉𝑝 +  𝐶𝑅𝐵𝐶 ∗ 𝑉𝑅𝐵𝐶
𝑉𝑏
 
(5) 
 
For TPM, the whole blood and plasma concentration will be different at low 
concentrations.  The difference depends on the concentration in the red blood cells and 
the volume of plasma and red blood cells in whole blood.  The concentration of the 
analyte in red blood cells relies upon the red blood cell-to-plasma partitioning 
(KRBC/plasma), which depends on the permeability of the cell membrane for the analyte and 
the affinity of the analyte for constituents within the plasma and red blood cells.
253,254
  As 
previously mentioned, TPM binds to carbonic anhydrase in the red blood cells in which 
TPM will have greater affinity to a constituent of red blood cells particularly at lower 
concentrations.
93
  Hematocrit values reflect the amount of red blood cells in whole blood.  
This varies between individuals with ranges for different age groups presented in Table 
22.
255
   
 
 
 
 
 
 
125 
 
Table 29: Normal Values for hematocrit per age  
Age Hematocrit (%)  (+ 2 SD) 
Birth 51 (42-64) 
<1 month 44 (31-67) 
1-2 months 35 (28-55) 
2-6 months  36 (28-42) 
0.5- 2 years 36 (33-40) 
2 to 6 years 37 (34-40) 
6-12 years 40 (35-45) 
Female 
         12-18 years 
         > 18 years 
 
41 (36-46) 
41 (36-44) 
Male 
         12-18 years 
         > 18 years 
 
43 (37-49) 
47 (41-50) 
 
The following equations relate the volume of whole blood to the volume of plasma and 
red blood cells, if the hematocrit is known.   
 
 𝑉𝑃 = (1 − 𝐻𝑐𝑡) ∗ 𝑉𝑏 (6) 
 
 𝑉𝑅𝐵𝐶 = 𝐻𝑐𝑡 ∗ 𝑉𝑏 (7) 
 
The red blood cell concentration can be calculated using the red blood cell-to-plasma 
partitioning and the concentration in plasma, equation 5. 
 
 𝐶𝑅𝐵𝐶 =  𝐾𝑅𝐵𝐶/𝑃𝑙𝑎𝑠𝑚𝑎 ∗ 𝐶𝑃 (8) 
 
When substituting these equations into equation 2, plasma concentration can be 
calculated from whole blood or DBS. 
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𝐶𝑃 =  
𝐶𝑏
(1 − 𝐻𝑐𝑡) +  𝐾𝑅𝐵𝐶/𝑝𝑙𝑎𝑠𝑚𝑎 ∗ 𝐻𝑐𝑡
 
(9) 
 
Plasma concentrations were calculated from the whole blood or DBS concentration using 
equation 9, where Cb is either whole blood or DBS.  The average hematocrit for the 
population in children (0.40 L/L), adult males (0.47 L/L) or females (0.41 L/L) and the 
value for KRBC/Plasma were entered as fixed values for this equation.   
 
Calculated plasma samples and analyzed plasma samples were compared using weighted 
Deming regression.  The agreement between the methods were compared using the 
Bland-Altman plot, a statistical method to compare two measurement techniques in 
clinical chemistry.
256
 This plot presents a graphical method in which the differences 
between the two techniques are plotted against the average of the difference of the two 
techniques.  This method has previously been used in comparison of blood spot 
measurement in LC-MS and plasma in FPIA of TPM.
241
  If the differences between 
measurements using the two assay methods lie within the limits of agreement of the 
Bland-Altman test 95% of the time, this indicates that the two methods are not producing 
different results.  All statistical analyses were conducted with GraphPad (Prism 6.0, San 
Diego, CA).  Acceptable criteria for the agreement between calculated and analyzed 
plasma concentrations were based on the guideline on Bioanalytical Method Validation 
of the FDA; the difference in concentration should be with +15% of their mean for at 
least 67% of the samples.
216
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5.4.3 Pharmacokinetic Analysis  
Population PK studies can identify and quantify sources of variability in parameter 
estimates in the patient population.  Samples can be collected from patients taking 
different doses over different periods of time.  As extensive samples from one person are 
not required, a population approach is useful for investigating patient groups that are 
difficult to study, such as premature infants.  The population PK approach will be used in 
analysis of the adult and children TPM concentration-time data.  
 
Steady-State Clearance  
The time of last dose and time of sample were recorded to determine the time after dose.  
Given TPM's long half-life and patients were on their maintance dosethe concentration 
measured was assumed to be close to the average steady state concentration.  The steady-
state clearance was calculated from the following equation for plasma and whole blood 
clearance and compared for each subject.   
 
 
𝐶𝑙 =  
(
𝐷𝑜𝑠𝑒
𝜏
)
𝐶𝑠𝑠
 
(10) 
Population Model 
The PK parameters were estimated using Phoenix software (WinNonLin, Version 6.3; 
Pharsight Corporation, Mountain View, CA, USA).  The first-order conditional 
estimation (FOCE) method produced estimates of the structural parameters, as well as 
estimates of inter-individual and residual unexplained variability for the PK parameters.  
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Model selection was based on the change in objective function value (OFV: for nested 
models), Akaike information criterion (AIC; for non-nested models), and the visual 
inspection of improvements in the diagnostic plots (observed vs. population and 
individual predicted concentrations and conditional weighted residuals vs. predicted 
concentration and time).  For testing covariate models, a decrease in the OFV greater than 
3.84 (α = 0.05, df = 1) between two nested models was considered significant.  
Demographic and clinical variables tested as potential covariates were age, sex, and 
concomitant medications (PHT and CBZ) where concomitant medications were included 
together.  The covariate model was built in a stepwise fashion with forward selection and 
backward deletion.  Each covariate was added to the base model one at a time in the 
forward selection based on previously described model selection criteria.  Covariates that 
did not increase the minimized OFV by more than 3.84 (α = 0.01, df = 1) were deleted 
from the full model. 
 
Both one- and two-compartment PK models with first-order absorption and elimination 
were tested to describe the plasma concentration–time profiles of TPM.  The analysis 
utilized sparse sampling methods with one data point per subject.  The time of sample 
collection and time of last dose were used to determine time after dose for each subject.  
The models were parameterized in terms of clearance (CL), volume of distribution (V), 
and first-order absorption rate constant (Ka).  The between-subject variability (BSV) was 
estimated using a multiplicative error model and expressed as a coefficient of variation 
(CV).  Plots of post hoc estimates of PK parameters from the base model versus 
covariates were visually inspected to evaluate the magnitude and direction of the 
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covariate effects.  A standard forward inclusion–backward elimination approach was 
adopted for developing the covariate model.  The covariates examined were age, sex, and 
comedication.  Continuous covariates, such as age, were modeled through linear 
regression on clearance.  The effect of categorical covariates (sex and comedication) was 
examined through a multiplicative model in order to obtain the fractional change in the 
PK parameters.   
 
Because the available concentration data contained little information about the absorption 
phase, absorption rate constant (ka) could not be estimated properly and was fixed at 2 h
-1
 
as used in previous reports.
139,140,143
  Additionally, the residual error was fixed at 15%.   
 
5.5 RESULTS 
Of the 38 recruited patients, 33 patients (adults: median age 36, range 21-55; children: 
median age 7, range 6-12) provided at least one usable spot and blood from a 
venipuncture.  Table 30 describes the demographics.  
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Table 30: Demographics  
Characteristics Adults Children 
Number of subjects 30 8 
Number of excluded DBS 5 0 
Number of missing venipuncture  1 0 
Male 14 (46.67%) 2 (25%) 
Age, median (Range) 
                  Males, median (Range) 
                  Females, median (Range) 
36 (21-55) 
40 (25-54) 
35 (21-55) 
7 (6-12) 
Hematocrit, median (Range) 
                   Males, median (Range) 
                  Females, median (Range) 
38 (27-49) 
40 (33-49) 
37 (27-41) 
35 (32-38) 
Drug Monitoring (mcg/ml), mean (standard deviation)  
                 Mean plasma levels 
                 Mean whole blood levels 
                 Mean DBS levels 
  
9.95 (7.92) 
11.33 (7.26) 
13.52 (5.26) 
 
7.56 (3.59) 
7.72 (4.03) 
7.51 (4.01) 
Average dose (mg/day), mean (standard deviation) 
                 Range (mg/day) 
357 (214) 
50-1400 
194 (80) 
60-350 
AED Concomitant Medications  
                 Enzyme Inducing (CBZ, PHT) 
                 Neutral (LTG, VPA, None) 
 
5 
25 
 
0 
8 
 
5.5.1 TPM Binding to Carbonic Anhydrase  
Whole blood and plasma concentrations were shown to be different.  Additionally, the 
whole blood-to-plasma ratio changed with plasma concentrations indicating that TPM is 
distributing into red blood cells.  The distribution into red blood cells may be due to its 
binding to carbonic anhydrase isoforms that are present in high concentrations in the 
erythrocytes.
251
  Figure 21 shows the whole blood/plasma concentration ratio for TPM as 
a function of the plasma concentration.  The figure suggests there is greater binding at 
lower concentrations and becomes saturated as plasma concentration increases.   
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Binding analysis revealed that binding comprised a saturable component (Figure 21).  
When a single binding site was assumed, the optimal fit yielded a KD of 0.5 mcg/ml (95% 
confidence interval, CI = 0.4-0.5) and a Bmax of 6.3 mcg/ml (95% confidence interval, CI 
= 6.2-6.5).  The two saturable binding site model was unable to fit the data and was over-
parameterized given the small sample size.         
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Figure 21: Plot of Whole Blood/Plasma Concentration Ratio for TPM as Function of 
the Plasma Concentrations.  The curvilinear line formed by a curve fit analysis of 
the data assuming one saturable binding site.  
 
Table 31: Final Parameter Estimates for Binding Model 
Parameter Units Estimate Std. Error %CV 
KD mcg/ml 0.5 0.04 8.6 
Bmax mcg/ml 6.3 0.08 1.2 
Random Unexplained Variability 5.9 % 0.01 21.5 
 
5.5.2 Estimation of Plasma Concentrations 
The analyzed concentration in blood was higher than the analyzed plasma concentration.  
The red blood cell-to-plasma partitioning coefficient appears to change with 
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concentration.  Thus, six different partitioning groups were formed based on 
concentration.  The red blood cell-to-plasma partitioning coefficient was determined to be 
12.2, 2.2, 1.5, 1.2, and 1.02 for whole blood concentration of 0-2.5 mcg/ml, 2.5-5 
mcg/ml, 5-10 mcg/ml, 10-15 mcg/ml, and greater than 15 mcg/ml, respectively.  The red 
blood cell-to-plasma partitioning coefficient was determined to be 17, 2.2, 1.6, 1.4, and 
1.0 for DBS concentration of 0-5 mcg/ml, 5-10 mcg/ml, 10-15 mcg/ml, 15-20 mcg/ml, 
and greater than 20 mcg/ml, respectively.  These values were established ex vivo using 
fresh human whole blood and calculating the RBC concentration in patients.  The 
partitioning is different between whole blood and DBS at the lower blood concentrations 
because the DBS concentration was slightly higher than whole blood concentrations due 
to greater recovery in the analytical method.   
 
Table 32: Red Blood Cell Partitioning  
Type of Assay Blood Concentration (mcg/ml) RBC-to-Plasma Partitioning 
Whole Blood 0-5 9.1 
 5-10 1.6 
 10-15 1.2 
 > 15 1.0 
DBS 0-5 17 
 5-10 2.2 
 10-15 1.6 
 15-20 1.4 
 >20 1.0 
 
Plasma concentrations were calculated from whole blood or DBS using equation 9, where 
individual hematocrit and average hematocrit for the population in children (0.40 L/L), 
adult males (0.47 L/L) or females (0.41 L/L) were used as fixed values.  The obtained 
KRBC/plasma (Table 32) from ex vivo and in vivo studies was used as fixed values given the 
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blood concentration.  Weighted Deming regression was used to investigate the 
relationship between calculated plasma concentrations from whole blood and DBS and 
analyzed plasma samples.  These relationships are shown in Figure 22.   
 
For whole blood, the slope was 0.97 (95% CI, 0.93 – 1.01), and the intercept was 0.41 
(95% CI, -0.04 – 0.86); and for DBS, the slope was 1.00 (95% CI, 0.94 – 1.06), and the 
intercept was -0.12 (95% CI, -0.76 – 0.52) when the population average hematocrit was 
used.  Additionally, when individual hematocrit was used the slope was 0.97 (95% CI, 
0.93 – 1.01), and the intercept was 0.56 (95% CI, 0.11 – 1.01) for whole blood; and for 
DBS, the slope was 1.06 (95% CI, 1.00 – 1.12), and the intercept was -0.29 (95% CI, -
0.90 – 0.33).   
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Figure 22: Calculated plasma concentrations, based on analyzed whole blood 
samples using average study hematocrit plotted against analyzed plasma 
concentrations (a) whole blood (N=37) (b) DBS (N=33). 
 
(a) 
(b) 
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The Bland-Altman difference plot (Figure 23) showed a small bias for the calculated 
plasma concentrations (WB: 0.16 mcg/ml, DBS: -0.09 mcg/ml) when using the average 
population hematocrit.  The blank line is the line of true identity, the dashed line is the 
mean observed difference, whereas the dotted lines resemble a 95% bias agreement.  
Calculated plasma concentrations based on individual hematocrit resulted in a 0.27 
mcg/ml and 0.25 mcg/ml biases for whole blood and DBS, respectively.  Mean calculated 
plasma concentrations were within + 15% of the mean of the analyzed plasma 
concentrations in 84% of the patient samples for whole blood and in 69% of the patient 
samples for DBS.    
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Figure 23: Bland-Altman plot for TPM using (a) whole blood (N=37) (b) DBS 
(N=33).   Bold dashed lines indicate the bias and dashed lines indicate the 95% 
confidence interval  
(b) 
(a) 
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The fixed values for hematocrit and KRBC/Plasma can be imputed into equation 9.  This 
results in a table (Table 33), which can be used to calculate plasma concentrations from 
whole blood concentrations.   
 
Table 33: Correction Values for Whole Blood TPM Concentrations Based on Age 
Group and Gender 
Group Whole Blood Concentration (mcg/ml) 
 0-5 5-10 10-15 >15 
Adult     
    Male 4.81 1.28 1.09 1.00 
    Female 4.32 1.25 1.08 1.00 
Children 4.24 1.24 1.08 1.00 
 
5.5.3 Pharmacokinetic Analysis  
Steady-State Clearance  
The distribution of TPM clearance for whole blood and plasma are shown in Figure 24.  
The mean clearance for plasma was 1.96 L/hr (SD=1.74) compared to 1.52 L/hr 
(SD=1.13) for whole blood.  Using a paired t-test, there was a significant difference 
between whole blood clearance and plasma clearance (p-value = 0.001). 
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Figure 24: Distribution of Plasma and Whole Blood Clearance.  Box-plot showing 
minimum to maximum clearance (N=37).  
 
In addition to the whole blood and plasma clearance, comedication effect on plasma 
clearance was explored.  The plasma clearance of TPM ranged from 0.5 L/hr to 5.3 L/hr.  
When patients were taking neutral AEDs the mean plasma clearance was 1.42 L/hr.   
Conversely, patients taking enzyme inducers showed mean plasma clearances of 3.52 
L/hr, respectively.  Inducing medication use did significantly alter clearance determined 
by a one-way ANOVA (p<0.0001).  The distribution of TPM plasma clearance based on 
comedication is displayed in Figure 25.     
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Figure 25: Distribution of Plasma Clearance Based on Comedication.  Box-plot 
showing minimum to maximum clearance (N=37).  
 
Population Model 
Final PK model parameter estimates and goodness-of-fit plots are presented in Table 34 
and Figure 26, respectively.  The final PK model was a one-compartment model with 
first-order absorption and elimination and a multiplicative model for BSV of CL/F.  
During the forward inclusion, only comedication showed a significant influence on the 
CL/F (ΔOFV = 209.91 and 199.5, respectively, P < 0.01).  A two-compartment model 
was unable to fit the data.  This is likely because of the small sample size and lack of 
samples at the early time points.     
 
Covariate analysis showed that concomitant medications with CBZ and PHT had a 
significant effect on clearance.  The patients with the highest clearance were on at least 
one inducing antiepileptic drug (carbamazepine or phenytoin).  Age and sex had no effect 
on clearance.   
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Table 34: Parameter estimates for final pharmacokinetic model 
Parameter Estimate 
(%RSE) 
95% CI BSV (%RSE) 
CL/F (L/hr) 1.43 (11.4) (1.1,1.8) 30.8% (18.7) 
   Effect of Inducer 0.82 (23.3) (0.42,1.21)  
V/F (L) 20.79 (27.5) (8.3,33.87) NE 
Ka (h
-1
) Fixed at 2   
Residual error (%) Fixed at 15% 
*RSE, relative standard error = (standard error ÷ estimate) × 100, NE, not evaluated; 95% 
CI from 500 bootstrap estimates; BSV, between-subject variability  
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Figure 26: Goodness-of-fit plots from the final PK model.  (a) Identity plots of 
observed vs. population predicated TPM concentration.  (b) Identity plot of 
observed vs. individual predicted TPM concentration.  (c) Scatter plot of conditional 
weighted residuals (CWRES) vs. time.  (d) Scatter plot of CWRES vs. population 
predicted TPM concentration.  Line of identity (solid); regression line (dashed) 
 
(a) 
(b) 
(c) (d) 
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Patients taking inducers have on average a larger or smaller clearance than those not 
taking inducing medications (see equation below).   
  
Clearance (L/hr) = 1.43 + 0.82 (if taking inducer) 
 
A sensitivity analysis was performed for the final model to determine the impact of the 
modeling assumptions (fixed ka) on the resulting structural and covariate parameter 
estimates.  The population PK model was fitted to the TPM data and values for ka were 
fixed to represent absorption half-lives of 0.23 to 0.69 hours.  This represented a range of 
plausible absorption times.  Results from the sensitivity analysis for ka are shown in 
Table 35.  CL/F estimates ranged from 1.47 to 1.53 L/hr, and V ranged from 20.28 to 
21.10 L over the range of ka values examined.  The values represent a <5% difference 
from the final model parameter estimates.  
 
Table 35: Sensitivity analysis results for ka 
Absorption t1/2 
(hr) 
Ka (hr
-1
) CL/F 
(L/hr) 
V/F (L) Inducing 
on CL 
BSVCL 
0.69 1 1.53 20.28 0.85 0.316 
0.46 1.5 1.50 21.04 0.83 0.311 
0.35 2 1.48 21.10 0.82 0.306 
0.28 2.5 1.48 21.03 0.81 0.302 
0.23 3 1.47 20.97 0.80 0.299 
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5.6 DISCUSSION   
This study examined the relationship between whole blood and plasma TPM 
concentrations and characterized the PK. Calculated TPM plasma concentration based on 
whole blood and DBS concentrations are in good agreement with analyzed plasma 
concentrations.  We showed that the difference between concentrations in whole blood or 
DBS and plasma can be explained well by the analyte-specific RBC-to-plasma 
partitioning and hematocrit using a formula from the literature.
253
  For whole blood and 
DBS, this formula resulted in a very small bias between calculated and analyzed plasma 
concentrations, only 0.16 mcg/ml and -0.09 mcg/ml, respectively.  Furthermore, 84% and 
69% of the calculated plasma concentrations in patients samples were within 15% of the 
analyzed plasma concentrations; we believe these biases are acceptable.  Additionally, in 
a clinical setting a 1-3 mcg/ml difference would be acceptable for clinical practice. 
 
The RBC-to-plasma partitioning was found to be dependent on the concentration.  
Therefore, groups were developed to be imputed as a fixed value across a concentration 
range.  Our target population consisted of adults and children receiving TPM treatment.  
The hematocrit variation between individual and population average was examined.  
Using each of these values, it was found that the biases ranged from 0.16 - 0.27 mcg/ml.  
The small biases indicate that for this application, it may not be necessary to impute 
patient-specific hematocrit values in the conversion formula and the average hematocrit 
for male, female, and children could be imputed as a fixed value.  This finding is 
important since hematocrit determination requires a venipuncture and would therefore 
diminish the large advantage of DBS sampling.  When using fixed values for both RBC-
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to-plasma partitioning and hematocrit, a table for the conversion of DBS/whole blood 
concentration to plasma concentration were created for adult males and females and 
children (values shown in Table 33).  This method provides a simple correction value for 
physicians or laboratory personnel.  Additionally, it appears that individual hematocrit (if 
available) and average hematocrit for the population can be used in the equations without 
significantly changing the calculated plasma concentration.  The hematocrit range for the 
patients in our study was 27 – 49%.  We did not find a correlation between whole blood 
concentration and hematocrit.  This could be because of the small range of hematocrit 
values in the patient population in this study.  Further studies would need to be performed 
to further examine the effect of hematocrit on whole blood concentration especially at 
younger ages when hematocrit is higher than adult values.  
 
This is the first study comparing TPM plasma and DBS concentration obtained from 
patient samples using a formula that includes both hematocrit and the analyte-specific red 
blood cell-to-plasma ratio.  This is especially interesting because the TPM RBC-to-
plasma partitioning coefficient changes with concentration which has not been calculated 
previously.  This study also showed that a 3 mm punch sample on a DBS card can be 
used to determine TPM concentrations in patients.  For most subjects in our study at least 
one usable DBS was obtained.  In the future, with proper training, patients could use this 
technique in order to keep the number of unusable spots to a minimum.   
 
In addition to the calculation of whole blood to plasma TPM concentrations, the binding 
of TPM to carbonic anhydrase was explored.  In our study (assuming one saturable site), 
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the Bmax and KD values was 6.3 and 0.5 mcg/ml, respectively.  These values are in good 
agreement of reported values for a one-site saturable binding model reported 
previously.
93
   
 
The mean clearance was 1.43 L/hr (SD= 1.10) in adults and children and was 
significantly affected by inducing comedication use.  Approximately 20% of TPM is 
metabolized when administered in the absence of enzyme inducers.
94
  When TPM is 
administered with an enzyme inducer, the metabolic clearance increases and up to 50% of 
the dose undergoes metabolism.
80,98,99
  The current study found a 5-fold range of 
clearance, from 0.5 L/hr to 5.3 L/hr.  The estimated TPM clearance obtained in this study 
is very similar to those obtained in previous studies.
91,93
  The narrow ranges of time after 
dose and concentrations in this study were limitations to investigating the population PK.  
These limitations result in an unreliable model for the estimation of volume of 
distribution.  Additionally, there was only one sample per subject which limits the intra-
subject variability that can be estimated.   
 
In the current study, a significant difference was observed between TPM clearance 
calculated from blood and plasma data.  There was a larger difference between plasma 
and whole blood clearances at lower concentrations.  This may be a result from a larger 
percentage of TPM being bound to carbonic anhydrase at lower concentrations and 
during drug elimination the release from these saturable binding sites contributes to 
reduced clearances for blood at low doses.  The volume of distribution was found to be 
lower than previous reported values.  As the 95% confidence interval obtained by 
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bootstrap method was extremely large it is likely that we could not obtain a good estimate 
of volume based on the limited data.   
 
The small sample size is a major limitation of the study and future studies need to 
confirm these results and further explore the hematocrit at younger ages.     
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CHAPTER 6: CONCLUSIONS  
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TPM is widely used in the treatment of epilepsy and migraines and is effective in 
controlling seizures in children and adults.  TPM has the potential to be an effective 
therapy of neonatal seizures and Dravet syndrome as discussed in Chapter 2.  One major 
hurdle in developing drugs for treatment of childhood seizure disorders is the severe 
restriction on blood sampling in critically ill children particularly infants and neonates, 
from whom blood is collected for a multitude of lab tests.  This circumstance reduces the 
blood volume available for PK studies.  Consequently, the necessary research on PK and 
dose finding is often significantly limited.   
 
One solution to this problem would be to use whole blood or DBS to measure drug 
concentrations in place of plasma.  This approach will reduce the volume of blood needed 
for a drug assay by greater than 75%.  Complicating the use of whole blood for TPM 
measurements is the fact that the drug exhibits saturable binding to carbonic anhydrases 
in RBCs.  As a result, there is a non-linear relationship between whole blood and plasma, 
which greatly complicates interpretation and comparison of TPM concentrations.
93
   
 
If TPM is measured in whole blood without correction for non-linear binding this would 
result in inaccurate PK estimates.  For example, Filippi et al used DBS to measure TPM 
concentrations in neonates.
109
  Blood values were corrected according to the patient’s 
hematocrit to obtain plasma values using an equation that assumed TPM is isolated in the 
plasma.  This will result in concentrations greater than what would be seen if properly 
correcting for TPM binding to RBCs.  The important aspect of this study is that this is the 
first report of TPM PK in newborns.  So, if you are trying to determine a dosing regimen 
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presenting these misleading concentrations could result in clinicians under dosing 
patients.  It is also important to establish this relationship between whole blood and 
plasma concentrations to correctly assess TPM PK and to establish a therapeutic range.   
 
With a DBS assay we could measure TPM concentrations in children while limiting the 
volume of blood that is collected.  The aim of this thesis research was to develop a 
sensitive and selective bioanalytical assay to quantify whole blood and DBS TPM 
concentrations, use the assay to measure whole blood in dogs and whole blood and DBS 
in adults and pediatrics, and implement these assays in clinical practice.  The results were 
then used to characterize the relationship between whole blood and plasma TPM 
concentrations. 
 
The availability of reliable and sensitive bioanalytical methods is a prerequisite in the 
determination of drug exposure in patients.  An HPLC-MS assay using plasma, whole 
blood, and DBS was developed according to FDA guidelines.  In particular, the DBS 
assay showed good performance on accuracy and precision.  TPM was shown to be stable 
in DBS when stored at -20°C for 6 months.  Whole blood and DBS concentrations are 
usually not similar to plasma concentrations, due to differences in analyte-specific red 
blood cell-to-plasma partitioning and patient-specific hematocrit.  The studies described 
in this thesis showed that the difference between whole blood and plasma can be 
explained using equation 9 (Chapter 5, page 123).  The red blood cell-to-plasma 
partitioning coefficient was found to be concentration dependent.  Therefore, groups 
based on whole blood or DBS concentration were formed and imputed as fixed values in 
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the equation.  Also, it was determined that hematocrit could be imputed as a fixed value 
depending on gender and age group.  When using fixed values for both red blood cell-to-
plasma partitioning and hematocrit, a simple table (Table 33) for the conversion of DBS 
concentrations to plasma concentrations was obtained.  
 
In the canine study, both intravenous and oral TPM were administered with the goal of 
comparing the PK of intravenous TPM in plasma and whole blood and describing the 
relationship between whole blood and plasma concentrations in dogs with naturally-
occurring epilepsy.  Whole blood and plasma samples were obtained at predetermined 
times up to 8 hours post-dose.  Similar to humans, the study showed a nonlinear 
relationship between plasma and whole blood TPM concentration in which whole blood 
TPM concentrations were 1.3-3.7 times greater than plasma concentrations.  Caution 
should be exercised in interpreting whole blood TPM concentrations as one may 
overestimate plasma concentrations by as much as 4 fold.  There was a difference in PK 
parameter estimates with those derived from whole blood generally showing reduced 
clearances resulting in longer elimination half-lives.  This difference is likely because 
during drug elimination, the release of TPM from high-affinity saturable binding sites in 
erythrocytes following low doses may contribute to the reduced clearance.  Future studies 
of TPM in other laboratory animals and dogs are needed to verify this relationship 
between plasma and whole blood.   
 
Assuming the rapid distribution of TPM from plasma to other body compartments 
includes the CNS, IV TPM may be useful in treating canine seizure emergencies and may 
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have potential use in human seizure emergencies.  Further study is needed on the use of 
IV TPM for seizure emergencies. 
 
In the adult and pediatric study, whole blood concentrations were found to be different 
from plasma concentrations.  This also led to a nonlinear relationship particularly at low 
concentrations.  These are the first studies comparing plasma and DBS concentration 
obtained from patient samples using a formula that includes both hematocrit and the 
analyte-specific red blood cell-to-plasma ratio.  In addition to the calculation of whole 
blood to plasma TPM concentrations, the binding of TPM to carbonic anhydrase was 
explored.  In our study (assuming one saturable site), the Bmax and KD values was 6.3 and 
0.5 mcg/ml, respectively.  These values are in good agreement with reported values for a 
one site saturable binding model reported previously.
93
  However, our sample size was 
small. 
 
The plasma and whole blood clearances are similar to previous reported values.  This 
further validates the plasma and whole blood assay for determination of TPM 
concentrations.  Further clinical research to investigate the value of TDM using DBS is 
warranted.  DBS can possibly be used by patients to self-sample at home and no special 
conditions for transport or storage are required.  It would be possible, in theory, to obtain 
a DBS sample on a regular basis.  This could provide information about compliance and 
individual differences. 
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In conclusion, the research described in this thesis shows that a whole blood and a DBS 
spot assay can be used to measure TPM concentration if the necessary corrections are 
used.  
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